

ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2010

Cancer in Slovenia



Rak
v Sloveniji

2010

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2010 / Cancer in Slovenia 2010

Uredniški odbor / Editorial Board

Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Katja Jarm,
Vera Pompe-Kirn, Primož Strojan, Vesna Zadnik,
Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Katja Jarm, Cveto Šval, Vesna Zadnik in Tina Žagar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo

Tisk / Printing

Littera Picta d.o.o.

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2010. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2013.

Cancer in Slovenia 2010. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2013.

Osebjje Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Darja Strle, Fani Škrlec, Polona Škulj,
Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:

<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

<http://www.slora.si/>
<http://www.slora.si/en/>

Uvod	7
Viri podatkov in metode registracije	9
Viri in nabor podatkov	9
Priprava podatkov za računalniško obdelavo	10
Kakovost podatkov RRRS in popolnost registracije	11
Statistične metode	12
Incidenca in umrljivost	12
Grobe in starostno specifične stopnje	12
Starostno standardizirane stopnje	12
Kumulativne incidenčne stopnje in kumulativno tveganje	13
Prevalenca	13
Relativno preživetje	14
Prebivalstvo Slovenije	15
Rak v Sloveniji 2010	16
Zahvala	19
Introduction	21
Data sources and methods of registration	23
Data sources and the list of data collected	23
Preparation of data for computer processing	24
Data quality and completeness of registration	25
Statistical methods	26
Incidence and mortality	26
Crude and age-specific rates	26
Age-standardised rates	26
Cumulative incidence rate and cumulative risk	27
Prevalence	27
Relative survival	28
Population of Slovenia	29
Cancer in Slovenia 2010	30
Acknowledgment	33
Reference / References	34

Slike / Figures

Slika 1:	Breme raka, Slovenija 2010.	36
Figure 1:	Cancer burden, Slovenia 2010.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2010.	36
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2010.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2010.	37
Figure 3:	The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2010.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2010.	38
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2010.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2010.	39
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex, Slovenia 1950–2010.	
Slika 6:	Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2001–2005 in 2006–2010 po spolu.	40
Figure 6:	Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2001–2005 and 2006–2010 by sex.	
Slika 7:	Petletno starostno standardizirano relativno preživetje (s 95 % intervalom zaupanja) odraslih bolnikov, zbolelih za izbranimi raki v letih 2000–2007, po evropskih regijah in v Sloveniji: rezultati raziskave EUROCORE-5.	43
Figure 7:	Five-year age-standardised relative survival (with 95% confidence interval) of adult patients diagnosed with selected cancers in 2000–2007 by European areas and in Slovenia: results of the EUROCORE-5 study.	
Slika 8:	Epidemiološke in klinične značilnosti rakov požiralnika, kardije in želodca po spolu, Slovenija 2006–2010.	44
Figure 8:	Epidemiological and clinical characteristics of oesophageal, cardia and gastric cancers by sex, Slovenia 2006–2010.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2001–2010 in 2013.	46
Table 1:	Observed and estimated cancer incidence, Slovenia 2001–2010 and 2013.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2010.	47
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2010.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2010.	48
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2010.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2010.	52
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2010.	
Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2010.	56
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2010.	

Tabela 6a:	Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2010.	62
Table 6a:	Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2010.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2010.	63
Table 6b:	Age standardised incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2010.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2010.	64
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2010.	
Tabela 8:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2010.	73
Table 8:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2010.	
Tabela 9:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2010.	76
Table 9:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2010.	
Tabela 10:	Incidenca malignih neoplazem limfatičnega in krvotvornega tkiva po verziji 2010 MKB-10, spolu in starosti, Slovenija 2010.	77
Table 10:	Incidence of malignant neoplasms of lymphoid and haemopoetic tissue according to version 2010 of ICD-10, by sex and by age, Slovenia 2010.	
Tabela 11a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.	79
Table 11a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 11b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	80
Table 11b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by surgery during their first treatment by primary site and treatment institution.	
Tabela 11c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po lokacijah raka in bolnici posega.	81
Table 11c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by systemic therapy during their first treatment by primary site and treatment institution.	
Tabela 12:	Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2010.	82
Table 12:	Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2010.	
Tabela 13:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2010.	83
Table 13:	Cancer mortality by site, by sex and by age, Slovenia 2010.	
Izbor publikacij / Selected publications		86



Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Inštitut za varovanje zdravja RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje onkološkega varstva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo še, kakšna je pričakovana incidenca raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2013); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953-1957 za leta 1951-1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957-1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljeni v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965-1977) in *Incidenca raka v Sloveniji* (1978-2006), in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978-1987*, *Preživetje bolnikov z rakom v Sloveniji 1963-1990*, *Preživetje bolnikov z rakom v Sloveniji 1983-1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991-2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih pet letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih* (*Cancer Incidence in Five Continents*), ki jih izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov pa je obdelano v mednarodnih raziskavah *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2010 (incidenca, prevalenca in preživetje) in Inštitut za varovanje zdravja (umrljivost) ter do evropskih in svetovnih podatkovnih zbirk o raku. S hitrim dostopom do tujih baz tako omogoča tudi primerjavo bremena raka z drugimi državami v Evropski uniji in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri in nabor podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00). Osnovni vir podatkov so *prijavnice rakave bolezni*. Regstru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavnici zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Inštitut za varovanje zdravja RS. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo sproti dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravneh. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispere v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), do takrat pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo, od poročila za leto 2001 njeno tretjo izdajo. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1.

V letošnjem poročilu prvič razvrščamo neoplazme limfatičnega in krvotvornega tkiva tudi v skladu z verzijo 2010 desete revizije Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10). Ta verzija ima bolezni limfatičnega in krvotvornega tkiva razvrščene na drug način kot tista iz leta 1995 in tako bolj odgovarja klinični obravnavi teh bolnikov.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961-1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejeni stadij vključeni tudi tumorji T3; pri materničnem vratu, telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejeni stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi

podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka osvetljujejo naslednji kazalci: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letošnjem letu (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunana na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število vseh umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno oz. umrljivostno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zbolí za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojčk pri ženskah 7,9/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojčk, ki je v tem primeru 7,9-odstotno. To pomeni, da bo 7,9 % deklic, rojenih leta 2010 (ali približno ena od 13), do 74. leta starosti verjetno zbolelo za rakom dojčk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih bolezni.

Relativno preživetje

Relativno preživetje je približek preživetja bolnikov kot v primeru, da bi upoštevali kot vzrok smrti samo izbranega raka. Izračuna se kot razmerje med opazovanim preživetjem proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki. Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Izračunano je s knjižnjico *relsurv* v programskem paketu R.

Opozarjamo še, da metoda, uporabljena za izračun relativnega preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati relativno preživetje na spletnem portalu SLORA. Za izračun relativnega preživetja na spletišču SLORA je uporabljena t.i. Hakulinenova ali popolna metoda izračuna relativnega preživetja. Po tej metodi prispevajo bolniki, ki jim zaradi predhodnega zaključka opazovanja ne sledimo polni čas, k relativnemu preživetju samo leta, za katera so dejanski podatki na voljo. Tako skupina zbolelih tri leta pred zaključkom opazovanja prispeva k eno- in triletnemu relativnemu preživetju, k petletnemu pa ne.

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 30. junij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki za leto 2010 o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	104.480	53.674	50.806
5–9	90.870	46.719	44.151
10–14	93.691	48.332	45.359
15–19	104.301	53.550	50.751
20–24	129.155	67.593	61.562
25–29	147.985	77.749	70.236
30–34	158.291	83.253	75.038
35–39	149.347	78.110	71.237
40–44	152.808	78.444	74.364
45–49	156.384	79.757	76.627
50–54	154.537	78.898	75.639
55–59	151.137	77.085	74.052
60–64	117.068	57.514	59.554
65–69	96.954	45.094	51.860
70–74	86.906	38.050	48.856
75–79	72.736	27.586	45.150
80+	82.611	23.308	59.303
Skupaj	2.049.261	1.014.716	1.034.545

Prebivalci Slovenije po starosti in spolu na dan 30. 6. 2010.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	119.349	58.096	61.253
Podravska	322.949	159.409	163.540
Koroška	72.713	36.499	36.214
Savinjska	260.039	129.760	130.279
Zasavska	44.483	21.763	22.720
Spodnjeposavska	70.790	35.509	35.281
JV Slovenija	141.810	71.460	70.350
Osrednjeslovenska	531.811	260.629	271.182
Gorenjska	203.192	100.344	102.848
Notranjsko-Kraška	52.256	26.372	25.884
Goriška	119.126	59.559	59.567
Obalno-Kraška	110.743	55.316	55.427
Slovenija	2.049.261	1.014.716	1.034.545

Prebivalci Slovenije po statističnih regijah in spolu na dan 30. 6. 2010.

Leta 2010 je za rakom zbolelo 12.896 ljudi, 6.885 moških in 6.011 žensk, umrlo pa 5.900 ljudi, 3.264 moških in 2.636 žensk (*Slika 1*). Od rojenih leta 2010 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2010 je živel 81.316 ljudi (34.584 moških in 46.732 žensk), ki so kdaj koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da bo leta 2013 za rakom zbolelo približno 14.000 prebivalcev Slovenije, približno 7.600 moških in 6.400 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Kljub temu, da se ogroženost z rakom zmerno večja, je največja v starejših letih; od vseh bolnikov z rakom je leta 2010 kar 58 % moških in 58 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (*Slika 2*). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije, svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), raki debelega črevesa in danke, prostate, dojke in pljuč – obsegajo 59 % vseh novih primerov rakavih bolezni (*Slika 3*). Raki teh organov so sicer povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač; ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z več kot 18 % vseh rakov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu rak dojke, dobra petina primerov vseh rakov (20,9 %). Pri obeh spolih so najpogostejšemu sledili nemelanomski kožni rak, rak debelega črevesa in danke ter pljučni rak (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 571 % pri moških in za 352 % pri ženskah; v zadnjih 10 letih se je pri moških večala za 3,3 % povprečno letno, pri ženskah pa za 2,5 %. Groba umrljivostna stopnja se je v zadnjih 10-ih letih večala pri moških za 1,8 % povprečno letno, pri ženskah pa za 2,3 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju letno le za 1,5 %, pri ženskah pa za 1,0 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*), pri moških za 1,1 % letno, pri ženskah pa za 0,9 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je poprej več umrlo zaradi rakave bolezni.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 85/100.000, v zadnjih letih se postopno manjša, strmo pa pljučnega raka prehitelata rak prostate ter rak debelega črevesa in danke. Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega

nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa PSA pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. V zadnjem desetletju se počasi manjša incidenčna stopnja raka glave in vratu. Pri ženskah se večajo incidenčne stopnje raka dojk, pljučnega raka in raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od leta 2003 počasi manjša. Pri obeh spolih se večja pogostost raka debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod v svetu pa je želodčnega raka pri obeh spolih vse manj (*Slika 5*).

Slika 6 prikazuje pet-letno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2006–2010 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2001–2005). Pri moških se je skupno preživetje povečalo za 6,3 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je pri tej bolezni preživetje večje kar za več kot 9 odstotnih točk. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Statistično značilno večje preživetje bolnikov z rakom danke je gotovo posledica odkrivanja bolezni v nižjem stadiju in večje kakovosti zdravljenja. Pri ženskah je skupno preživetje večje za 0,7 odstotne točke. Preživetje bolnic z rakom dojk se je izboljšalo za 2,2 odstotne točke, večje preživetje pa so imele tudi bolnice z rakom ščitnice, danke, pljuč in kožnim melanomom.

V decembru 2013 so bili objavljeni izsledki raziskave EURO-CARE-5, ki obravnava preživetje več kot 10 milijonov bolnikov z rakom, starejših od 15 let, zbolelih v letih 2000–2007 v 29 evropskih državah. *Slika 7* prikazuje pet-letno starostno standardizirano relativno preživetje bolnikov z desetimi najpogostejšimi mesti raka po evropskih regijah in v Sloveniji, skupaj z evropskim povprečjem. V Sloveniji je bilo od evropskega povprečja večje preživetje bolnic in bolnikov z želodčnim rakom, za povprečjem pa je še najbolj zaostajalo preživetje bolnikov z rakom prostate.

Po Mednarodni klasifikaciji bolezni in sorodnih zdravstvenih problemov ima želodčni rak skupaj z rakom kardije kodo C16. Čeprav naj bi šlo za en organ, pa ima rak kardije drugačne epidemiološke značilnosti kot rak drugih delov želodca; v svetu in tudi pri nas se incidenčna stopnja raka kardije zmeroma večja, medtem ko se incidenčna stopnja drugih predelov želodca manjša. Na *Sliki 8* prikazujemo epidemiološke in klinične značilnosti raka požiralnika in želodčnega raka, posebej kardije in posebej drugih delov želodca.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2010 pri 93,8 % od 12.896 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,8 % z drugimi preiskavami, le 0,3 % primerov pa je bilo v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti. Ta, zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, kako se primeri razporejajo po 5-letnih starostnih skupinah prikazuje *Tabela 4*, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembne za načrtovanje zdravstvenih zmogljivosti, starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Kakšna je bila morfološka slika malignomov pri 11.518 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ektranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ektranodalnih lokacij majhno, so prikazane le absolutne številke.

Tabela 10 letos objavljamo prvič. V njej je prikazana starostna porazdelitev neoplazem limfatičnega in krvotvornega tkiva v skladu z verzijo 2010 desete revizije Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10).

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2010. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 13* so uradni podatki o umrljivosti za rakom v letu 2010; zbira jih Inštitut za varovanje zdravja RS.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič. Patologinja dr. Gorana Gašljevič nam je pomagala pravilno opredeliti histološke izvide.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Inštituta za varovanje zdravja RS in Statističnega urada RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor



Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS together with the Unit of Epidemiology is merged in a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been underway since 2007 (Registry DORA).

The data on cancer, that are collected by the CRRS, incidence, survival and prevalence, serve together with mortality data, collected by the Institute of Public Health as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of all levels of cancer control, primary prevention, diagnosis, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentre studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of CRRS are one of the regular ways of disseminating information on cancer among professionals and all other groups. As we are limited by the technology of data collection because of a variety of data sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. As preliminary information on expected incidence in the year when the Annual Report is published (in this report for the year 2012), estimated numbers and rates are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951-1955 were issued during the years 1953-1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957-1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, first entitled *Cancer in Slovenia* (1965-1977), and then *Cancer Incidence in Slovenia* (1978-2006). Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978-1987*, *Cancer Patients' Survival in Slovenia 1963-1990*, *Cancer Patients' Survival in Slovenia 1983-1997* and *Survival of Cancer Patients, diagnosed in 1991-2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the *Cancer Incidence in Five Continents* issued by International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCORE-2*, *EUROCORE-3*, *EUROCORE-4*, *EUROCORE-5*, *RARECARE* and *EUNICE*.

In 2010, the Registry's database has been upgraded and data processing modernized. At that time an interactive web portal with the name SLORA was launched also. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAK/cancer". It is available at www.slora.si. It enables a simple access to data on cancer in Slovenia, registered in CRRS, currently till 2009 (incidence, prevalence and survival) or Institute of Public health (mortality) and comparison with other countries in the European Union and in the world. It describes the data and informs users with professional explanations about cancer risk factors, about screening and early detection and treatment outcome.

Data sources and the list of data collected

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92 and 65/00). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data, gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from Institute of Public health of RS. A lot of time of CRRS's staff is needed for queries about patients, from who we do not have all data or we get their data at death only.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established through a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up, the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as date of loss. From 1985, since the uniform personal ID number has been used in Slovenia, in CRRS the percentage of the lost to follow-up is below 1%, in patients registered in the last decade being 0.1%.

When analysing the spatial distribution of cancer, the new law on regional division of Slovenia is followed, that in the year 2000 introduced the system of division of Slovenian territory at eleven levels. The exact mapping of patients' permanent address is also possible, as we maintain the regular connection with the Registry of spatial units of the Surveying and Mapping Authority. Till the Annual Report 2002, the data have been presented by 9 health regions in Table 6, since then, 12 statistical regions are used to present the data.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRS specially trained nurses code the data retrieved from notifications in accordance with the internationally and in CRRS agreed rules.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related health Problems (ICD-10); before, the 8th revision was used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001 on. In this edition, some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. Gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to this classification, chronic myeloproliferative disorders and myelodysplastic syndromes are classified as malignant (currently C96.7 topography code) as well as polycythaemia, assigned the code C94. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56).

In this report, malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are coded also according to Version for 2010 of 10th revision of the International Statistical Classification of Diseases and Related health Problems. In this Version, the classification of lymphoid and haematopoietic malignant neoplasms is different from the one in Version 1995, but more suitable for clinical management of these patients.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961-1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasm (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered.

For stage description, a simplified definition of stages at diagnosis is used, classifying them in localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In solid tumors, the simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer, T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (exceptions already mentioned) and/or regional node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Stage according to TNM or any other appropriate classification is also stored in the CRRS database, if available. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry, which are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patient record in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to get information about their vital status and among them we often find cases that have not been entered in the CRS database yet.

The registration is more complete where the registries have access to death certificates, and can send out additional inquiries about disease for the deceased that have not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. on the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country, where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2010 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 population, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (=incidence or mortality), divided by the number of persons at risk of disease (or death) at the beginning of time interval; it is expressed per 100,000 person-years. The *age specific rate* expresses incidence or mortality rate in an individual five-year age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardised rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardised rates by direct method are presented, using World, European and Slovenian standard population. Age standardised mortality rates are also available at SLORA web-portal. In Table 6b the standard is the age structure of Slovenian 2002 census population. The standard population is always the same for both sexes that may in some situations result in standardized rate being bigger than crude rate in one sex, usually in males, who are on average younger, and smaller in females.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 population. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk (CR) is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CR = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 7.9/100 can be used to estimate cumulative risk of breast cancer that is in this case 7.9%. This means that 7.9% of women born in 2010 (approximately each 13th woman) are expected to develop breast cancer by their age of 75 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of time, when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diseases.

Relative survival

Relative survival is an approximation of patients' survival in the case where the observed cancer would be considered as the only cause of death. Relative survival is a ratio between the observed and the expected survival, i.e. the survival expected with respect to gender and age in certain time period in the whole population the patients come from. The expected survival is calculated from general mortality data, published routinely in the form of mortality tables for an individual country within the framework of its vital statistics. The relative survival for the needs of this report was calculated using the Slovenian annual complete yearly life tables, using package *relsurv* in statistical software R.

It should be noted that the method, used for survival calculation in this report is different from the one used to present survival at web-portal SLORA, where the relative survival is computed by complete or Hakulinen's method. In this method the patients followed up for a shorter period of time are considered in the calculation only for the time when they were actually followed. Thus, a group diagnosed three years before the completion of study, contributes to one- and three-year complete relative survival but not also to five-year survival.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports, the number of population on June 30 of a particular year is used, that is obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2009 by age and by sex are presented.

Age	Total	Males	Females
0–4	104,480	53,674	50,806
5–9	90,870	46,719	44,151
10–14	93,691	48,332	45,359
15–19	104,301	53,550	50,751
20–24	129,155	67,593	61,562
25–29	147,985	77,749	70,236
30–34	158,291	83,253	75,038
35–39	149,347	78,110	71,237
40–44	152,808	78,444	74,364
45–49	156,384	79,757	76,627
50–54	154,537	78,898	75,639
55–59	151,137	77,085	74,052
60–64	117,068	57,514	59,554
65–69	96,954	45,094	51,860
70–74	86,906	38,050	48,856
75–79	72,736	27,586	45,150
80+	82,611	23,308	59,303
Total	2,049,261	1,014,716	1,034,545

Population of Slovenia by age and by sex, June 30, 2010.

In the number of population by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Statistical region	Total	Males	Females
Pomurska	119,349	58,096	61,253
Podravska	322,949	159,409	163,540
Koroška	72,713	36,499	36,214
Savinjska	260,039	129,760	130,279
Zasavska	44,483	21,763	22,720
Spodnje-posavska	70,790	35,509	35,281
JV Slovenija	141,810	71,460	70,350
Osrednjeslovenska	531,811	260,629	271,182
Gorenjska	203,192	100,344	102,848
Notranjsko-Kraška	52,256	26,372	25,884
Goriška	119,126	59,559	59,567
Obalno-Kraška	110,743	55,316	55,427
Slovenia	2,049,261	1,014,716	1,034,545

Population by Slovenian statistical regions and by sex, June 30, 2010.

In 2010, 12,896 patients were diagnosed with cancer, 6,885 males and 6,011 females, and 5,900 patients died from cancer, 3,264 males and 2,636 females (*Figure 1*). From those born in 2010, one in two males and one in three females are expected to develop cancer by their age of 75 (*Table 5*).

At the end of December 2010, there were 81,316 people (34,584 males and 46,732 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated, that in 2013, there will be about 14,000 Slovenian inhabitants newly diagnosed with cancer, approximately 7,600 males and 6,400 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

Though the risk of cancer is slowly increasing, the risk is the highest in older age groups; from all cancer patients, diagnosed in 2010, 58% of males and 58% females were aged 65 or more at diagnosis. Less than 1% of all cancer is among children and young adults (till the age of 20) (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, in *Table 2* besides crude also age standardised rates are presented. For better comparison with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian were applied.

First five most frequent cancers (skin – except melanoma, colorectal, prostate, breast and lung) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2010 was prostate (*Figure 3*). In females, breast was the most frequent cancer site with 20.9% of all new cases. In both sexes, these cancer sites were followed by skin (non-melanoma), colorectum and lung (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased for 571% in males and for 352% in females. In the last 10 years, the average annual increase in males was 3.3% and 2.5% in females. The crude mortality rate in the last 10 years increased on average by 1.8% per year in males and by 2.3% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 1.5% and 1.0% in females. Cumulative mortality rate is decreasing in both sexes in the last 10 years, in males on average by 1.1% and in females on average by 0.9% annually. The decreasing mortality, despite increasing incidence, indicates improvement of treatment of cancer patients and is a proof that they are cured of, not dying from cancer.

The time trend of common cancers in males shows that lung cancer incidence was increasing since the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing; it was overcome by prostate and colorectal cancer. The huge increase in prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of PSA test as an opportunistic

screening method, resulting in detection of many cancers that would never progress or even not be detected during lifetime without screening. In the last 10 years the incidence rate of head and neck cancer is slowly decreasing. In females, the incidence rate of breast cancer is increasing, while the incidence of cervical cancer is slowly decreasing since 2003. In both sexes, the incidence of cancers of colon and rectum, melanoma and other skin is increasing as in other countries, while the incidence of stomach cancer is decreasing (*Figure 5*).

In *Figure 6*, 5-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites is presented of those, diagnosed in 2006–2010 and for comparison of those diagnosed in 2001–2005. In males the overall survival increased for 6.3 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients the survival increased for 9 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. Better relative survival of patients with rectal cancer is probably due to earlier stage at diagnosis and better treatment. In females, the overall survival increased for 0.7 percentage points. In breast cancer patients it increased for 2.2 percentage points, while it increased also for patients with cancers of thyroid, rectum, lung and skin melanoma.

In December 2013, the results of EURO-CARE-5 study have been published. It compares 5-year survival from diagnosis for more than 10 million adults diagnosed between 2000 and 2007 in 29 European countries. On *Figure 7* age-standardised relative 5-year survival of patients with 10 most frequent cancer sites by European regions and Slovenia together with European average is presented. Survival of Slovenian stomach cancer patients was above the European average, while most below the European average was survival of Slovenian prostate cancer patients.

According to the 10th revision of the International Statistical Classification of Diseases and Related health Problems, stomach cancer is coded as C16. Cardia is a part of stomach, but it has different epidemiological characteristics; incidence rate of cardia cancer is slowly increasing in the world and in Slovenia, while incidence rate of cancer of other parts of stomach is decreasing. On *Figure 8* some epidemiological and clinical characteristics of oesophagus, cardia and stomach cancer are presented.

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2010, in 93.8 % from 12,896 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 5.8% with other investigations and only 0.3% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents those patients that, due to advanced age or disease have not been treated in the hospital. *Table 3* presents the number of new cases by cancer site, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

The morphology of tumours in 11,518 cases, diagnosed microscopically, is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, that takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extranodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extranodal sites, only the absolute numbers are given.

Table 10 is new and shows the age distribution of malignant neoplasms of lymphoid, haematopoietic and related tissue according to Version for 2010 of 10th revision of the International Statistical Classification of Diseases and Related health Problems (ICD-10).

Table 11 presents basic data on cancer patients treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b and 11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at Institute of Oncology Ljubljana only (with few exceptions, that have been irradiated abroad).

In *Table 13*, there are official data on cancer mortality in 2009. The table has been prepared at the Institute of Public Health of the Republic of Slovenia.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other health institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought for the additional necessary information. If the data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Ana Dotzauer in Mrs. Maruška Ferjančič from the Ljubljana Institute of Oncology Hospital Registry. The pathologist Dr. Gorana Gašljević helped us with proper coding of histological diagnoses.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, Institute of Public Health, and Statistical Office with the Cancer Registry.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264-77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961-1966.
- World health statistics report. Geneva: World Health Organization, 1970-1974.
- Rak v Sloveniji (1965-77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967-1980.
- Incidenca raka v Sloveniji (1978-2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981-2004.
- Doll R, Payne P, Waterhouse J, eds. *Cancer incidence in five continents*. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. *Cancer incidence in five continents*. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. *Cancer incidence in five continents*. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. *Cancer incidence in five continents*. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. *Cancer incidence in five continents*. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. *Cancer incidence in five continents* Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. *Cancer incidence in five continents*. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. *Cancer incidence in five continents*. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. *Cancer incidence in five continents*. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. *Cancer Incidence in Five Continents, Vol. X (electronic version)* Lyon, IARC, 2013. <http://ci5.iarc.fr>.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. *Survival of cancer patients in Europe: the EUROCORE-2 study*. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. *Survival of cancer patients in Europe: the EUROCORE-3 study*. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773-83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5—a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, L Botta, S Rossi et al. Childhood cancer survival in Europe 1999–2007: results of EUROCORE-5—a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47; 2493-511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. *Zemljevidi incidence raka v Sloveniji 1978-1987 (Atlas of cancer incidence in Slovenia 1978-1987)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. *Preživetje bolnikov z rakom v Sloveniji 1963-1990 (Cancer patients' survival in Slovenia 1963-1990)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. *Preživetje bolnikov z rakom v Sloveniji 1983-1997 (Cancer patients' survival in Slovenia 1983-1997)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia)*. Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.

- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolesi, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International classification of diseases for Oncology. Geneva: World Health Organisation, 2000.
- World Health Organisation. International statistical classification of diseases and related health problems. - 10th revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751-66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2013. URL: <http://pxweb.stat.si/>.
- Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272-8.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.


Slika 1: Breme raka, Slovenija 2010.

Figure 1: Cancer burden, Slovenia 2010.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2010.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2010.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2010.
 Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2010.



MOŠKI IN ŽENSKÉ / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danko / Colorectum (C18–C20)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64–C65)


Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2010.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2010.




Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2010.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex, Slovenia 1950–2010.




Slika 6: Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2001–2005 in 2006–2010 po spolu.

Figure 6: Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2001–2005 and 2006–2010 by sex.




Slika 6: Nadaljevanje.
Figure 6: Continued.



Slika 7: Petletno starostno standardizirano relativno preživetje (s 95 % intervalom zaupanja) odraslih bolnikov, zbolelih za izbranimi raki v letih 2000–2007, po evropskih regijah in v Sloveniji: rezultati raziskave EUROCORE-5.

Figure 7: Five-year age-standardised relative survival (with 95% confidence interval) of adult patients diagnosed with selected cancers in 2000–2007 by European areas and in Slovenia: results of the EUROCORE-5 study.



Slika 8. Epidemiološke in klinične značilnosti rakov požiralnika, kardije in želodca po spolu, Slovenija 2006–2010.
Figure 8. Epidemiological and clinical characteristics of oesophageal, cardia and gastric cancers by sex, Slovenia 2006–2010.

MOŠKI / MALES

	Požiralnik (C15)	Kardija (C16.0)	Želodec (C16.2–C16.9)
BREME RAKA			
Povprečno letno število primerov (N)	69	52	233
Groba incidenčna stopnja na 100.000	7	5	23
Ocenjeni delež letne spremembe grobe incidenčne stopnje zadnjih 10 let (%)	-2,3 % ⁺	3,1 % ⁺	-1,3 % ⁺
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%)	-4,2 % ⁺	0,6 %	-3,7 % ⁺
Celotna prevalenca (na dan 31. 12. 2010)	116	737	860
NAČIN UGOTOVITVE (povprečno letno število (% od N))			
Mikroskopsko potrjeni	65 (93,6 %)	50 (95,4 %)	223 (95,9 %)
Ugotovljeni z drugimi preiskavami	4 (6,1 %)	2 (4,2 %)	7 (2,9 %)
Registrirani samo iz zdravniških poročil o vzroku smrti (ZPS)	0,2 (0,3 %)	0 (0 %)	3 (1,1 %)
STADIJ (povprečno letno število (% od N))			
Omejen	12 (17,4 %)	7 (14,3 %)	44 (18,7 %)
Razširjen	28 (41,2 %)	24 (46,3 %)	85 (36,7 %)
Razsejan	19 (28,1 %)	18 (34,0 %)	89 (38,3 %)
Neznan	9 (13,3 %)	3 (5,4 %)	15 (6,3 %)
NAČIN PRVEGA ZDRAVLJENJA (povprečno letno število (% od N brez ZPS primerov))			
Kakorkoli zdravljeni	38 (55,5 %)	33 (64,5 %)	134 (58,2 %)
Operacija *	11 (15,4 %)	15 (28,6 %)	89 (38,6 %)
Predoperativno obsevanje	2 (2,3 %)	2 (4,6 %)	2 (0,8 %)
Pooperativno obsevanje	2 (2,9 %)	7 (13,1 %)	27 (11,9 %)
Obsevanje **	21 (30,2 %)	4 (8,5 %)	5 (2,3 %)
Sistemsko zdravljenje ***	3 (4,7 %)	5 (9,7 %)	11 (4,7 %)

* Operacija brez obsevanja, lahko v kombinaciji s sistemskim zdravljenjem


*** Samo sistemsko zdravljenje

** Obsevanje brez operacije, lahko v kombinaciji s sistemskim zdravljenjem

+ p < 0,05


Povprečna letna starostno specifična incidenčna stopnja, Slovenija 2006–2010.

Požiralnik (C15) ■
Kardija (C16.0) ■
Želodec (C16.2-C16.9) ■



Triletno drseče povprečje grobo in starostno standardizirane (SSS; evropski standard) incidenčne stopnje, Slovenija 1961–2010.

Požiralnik (C15); groba stopnja —
Požiralnik (C15); SSS —
Kardija (C16.0); groba stopnja —
Kardija (C16.0); SSS —
Želodec (C16.2-C16.9); groba stopnja —
Želodec (C16.2-C16.9); SSS —



Slika 8: Nadaljevanje.
Figure 8: Continued.

ŽENSKÉ / FEMALES


	Oesophagus (C15)	Cardia (C16.0)	Stomach (C16.2–C16.9)
CANCER BURDEN			
Average annual number of cases (N)	16	15	164
Crude incidence rate per 100,000	2	1	16
Estimated annual change of crude incidence rate in the latest 10 years (%)	-1.7 %	1.8 %	-0.5 %
Estimated annual change of ASR in the latest 10 years (%)	-3.8 % ⁺	1.4 %	-2.4 % ⁺
Lifetime prevalence (on December 31, 2010)	35	51	737
BASIS OF DIAGNOSIS (average annual number (% of N))			
Microscopically confirmed	14 (87.8%)	15 (98.7%)	157 (95.3%)
Confirmed by other investigations	2 (9.8%)	0.2 (1.3%)	6 (3.6%)
Registered from death certificates only (DCO)	0.4 (2.4%)	0 (0%)	2 (1.1%)
STAGE (average annual number (% of N))			
Localized	3 (19.5%)	1 (7.9%)	35 (21.4%)
Regional	7 (43.9%)	7 (46.1%)	60 (36.7%)
Distant	4 (24.4%)	6 (39.5%)	53 (32.2%)
Unknown	2 (12.2%)	1 (6.6%)	16 (9.6%)
FIRST TREATMENT MODE (average annual number (% of N except DCO cases))			
Any treatment	7 (41.3%)	8 (55.3%)	90 (55.4%)
Treated by surgery*	2 (13.8%)	4 (27.6%)	62 (38.1%)
Preoperative radiotherapy	0.6 (3.8%)	0.6 (3.9%)	1 (0.7%)
Postoperative radiotherapy	0 (0%)	2 (11.8%)	18 (11.3%)
Treated by radiotherapy**	4 (22.5%)	1 (6.6%)	1 (0.9%)
Treated by systemic therapy***	0.2 (1.3%)	0.8 (5.3%)	7 (4.3%)

* Surgery not combined with radiotherapy, but in some cases combined with systemic therapy
** Radiotherapy not combined with surgery, but in some cases combined with systemic therapy

*** Systemic therapy only
+ p < 0.05

Average annual age specific incidence rate, Slovenia 2006–2010.

Oesophagus (C15) ■
Cardia (C16.0) ■
Stomach (C16.2–C16.9) ■



Three year moving average of the crude and age standardized (ASR; European standard) incidence rate, Slovenia 1961–2010.

Oesophagus (C15); crude rate —
Oesophagus (C15); ASR —
Cardia (C16.0); crude rate —
Cardia (C16.0); ASR —
Stomach (C16.2–C16.9); crude rate —
Stomach (C16.2–C16.9); ASR —




Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2001–2010 in 2013.

Table 1: Observed and estimated cancer incidence, Slovenia 2001–2010 and 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2001–2005		Povprečne letne opazovane vrednosti 2006–2010		Ocena za 2013			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Estimation for 2013			
			Average annual observed values 2001–2005		Average annual observed values 2006–2010		Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
		Number	Incidence rate per 100,000	Number	Incidence rate per 100,000					
C00–C96	Vse lokacije All sites	M+Ž	10411	521,4	12169	599,8	13988	13680–14296	679	664–694
		M	5362	548,9	6477	646,9	7612	7383–7841	747	724–769
		Ž	5049	495,2	5692	553,9	6377	6170–6583	613	593–633
C00–C14	Usta in žrelo Mouth and pharynx	M	256	26,2	272	27,2	284	238–330	28	23–32
		Ž	63	6,2	67	6,5	76	53–100	7	5–10
C15	Požiralnik Oesophagus	M	77	7,9	69	6,9	62	41–82	6	4–8
		Ž	18	1,7	16	1,6	15	5–25	1	0–2
C16	Želodec Stomach	M	295	30,2	285	28,4	277	234–320	27	23–31
		Ž	185	18,2	180	17,5	177	141–214	17	14–21
C18	Debelo črevo Colon	M	367	37,6	474	47,3	600	535–664	59	53–65
		Ž	311	30,5	376	36,6	443	389–498	43	37–48
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	319	32,7	392	39,2	463	406–520	45	40–51
		Ž	223	21,9	252	24,5	275	230–319	26	22–31
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	93	9,5	113	11,3	129	98–160	13	10–16
		Ž	42	4,1	48	4,7	50	29–71	5	3–7
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	52	5,4	63	6,3	74	51–97	7	5–10
		Ž	82	8,1	102	9,9	124	95–153	12	9–15
C25	Trebušna slinavka Pancreas	M	122	12,5	161	16,1	185	148–221	18	15–22
		Ž	138	13,5	165	16,1	201	164–238	19	16–23
C32	Grlo Larynx	M	98	10,0	98	9,8	89	65–113	9	6–11
		Ž	12	1,2	10	1,0	10	2–18	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	855	87,6	887	88,7	907	823–991	89	81–97
		Ž	282	27,7	341	33,2	411	359–463	40	34–45
C43	Maligni melanom kože Malignant melanoma of skin	M	145	14,8	212	21,1	277	234–319	27	23–31
		Ž	169	16,6	235	22,9	286	242–330	27	23–32
C44	Druge maligne neoplazme kože Skin, other malignomas	M	709	72,6	939	93,8	1204	1113–1295	118	109–127
		Ž	793	77,8	1008	98,1	1229	1138–1321	118	109–127
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	30	3,0	26	2,6	24	10–38	2	1–4
		Ž	30	3,0	37	3,6	44	26–62	4	2–6
C50	Dojka Breast	M	10	1,0	8	0,8	7	0–14	1	0–1
		Ž	1074	105,3	1170	113,9	1269	1175–1363	122	113–131
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	196	19,2	144	14,0	115	91–139	11	9–13
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	299	29,4	292	28,4	293	247–339	28	24–33
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	177	17,4	172	16,8	169	133–204	16	13–20
C61	Prostata Prostate	M	794	81,3	1172	117,0	1578	1476–1680	155	145–165
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	93	9,5	101	10,1	100	74–126	10	7–12
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehonom Kidney with renal pelvis	M	165	16,9	212	21,2	266	224–308	26	22–30
		Ž	93	9,1	109	10,6	135	103–167	13	10–16
C67	Sečni mehur Bladder	M	189	19,3	199	19,9	223	182–264	22	18–26
		Ž	68	6,6	76	7,4	85	60–109	8	6–11
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	74	7,6	83	8,3	87	68–106	9	7–10
		Ž	65	6,4	62	6,1	68	51–85	7	5–8
C73	Ščitnica Thyroid gland	M	27	2,8	32	3,2	40	22–57	4	2–6
		Ž	92	9,0	117	11,4	145	114–175	14	11–17
C81	Hodgkinova bolezen Hodgkin's disease	M	26	2,6	28	2,8	27	17–38	3	2–4
		Ž	23	2,3	23	2,2	24	11–37	2	1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	117	12,0	134	13,4	148	123–173	15	12–17
		Ž	130	12,7	137	13,4	148	123–173	14	12–17
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	41	4,2	65	6,5	88	63–112	9	6–11
		Ž	51	5,0	58	5,7	65	43–86	6	4–8
C91–C95	Levkemije Leukaemias	M	116	11,9	143	14,3	154	128–180	15	13–18
		Ž	99	9,7	109	10,6	117	94–139	11	9–13

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2010.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2010.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	12896	629,3	331,2	471,2	556,6
		M	6885	678,5	393,6	572,4	687,2
		Ž	6011	581,0	286,0	400,1	466,7
C00–C14	Usta in žrelo Mouth and pharynx	M	295	29,1	17,5	24,6	27,5
		Ž	74	7,2	3,7	5,0	5,8
C15	Požiralnik Oesophagus	M	63	6,2	3,5	5,2	6,1
		Ž	20	1,9	0,6	1,0	1,3
C16	Želodec Stomach	M	278	27,4	15,0	23,1	28,4
		Ž	190	18,4	7,2	10,9	13,4
C18	Debelo črevo Colon	M	565	55,7	31,5	46,7	56,0
		Ž	434	42,0	18,7	27,5	32,5
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	450	44,3	25,7	37,4	44,5
		Ž	260	25,1	11,3	16,6	19,5
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	106	10,4	6,4	8,9	10,6
		Ž	51	4,9	1,9	2,9	3,6
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	58	5,7	3,1	4,8	6,0
		Ž	98	9,5	3,4	5,3	6,6
C25	Trebušna slinavka Pancreas	M	154	15,2	8,5	12,7	15,6
		Ž	171	16,5	5,9	9,2	11,5
C32	Grlo Larynx	M	112	11,0	6,7	9,4	10,9
		Ž	8	0,8	0,5	0,7	0,8
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	858	84,6	47,9	70,7	84,0
		Ž	387	37,4	17,2	25,2	29,0
C43	Maligni melanom kože Malignant melanoma of skin	M	229	22,6	14,3	19,4	22,7
		Ž	240	23,2	13,5	17,6	20,2
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1043	102,8	56,5	86,0	107,0
		Ž	1058	102,3	44,3	64,7	78,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	18	1,8	1,1	1,5	1,8
		Ž	37	3,6	1,6	2,3	2,7
C50	Dojka Breast	M	12	1,2	0,7	1,0	1,1
		Ž	1255	121,3	68,8	93,3	105,1
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	142	13,7	9,4	11,9	13,2
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	324	31,3	15,8	22,3	25,9
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	172	16,6	9,7	12,8	14,4
C61	Prostata Prostate	M	1267	124,9	71,1	104,6	127,8
		Ž	–	–	–	–	–
C62	Modo Testis	M	104	10,2	8,8	9,4	10,1
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	242	23,8	14,1	20,2	23,7
		Ž	113	10,9	4,8	6,9	8,3
C67	Sečni mehur Bladder	M	202	19,9	10,6	16,6	20,8
		Ž	71	6,9	2,4	3,8	4,7
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	85	8,4	5,6	7,3	8,3
		Ž	78	7,5	4,8	6,0	6,6
C73	Ščitnica Thyroid gland	M	39	3,8	2,7	3,4	3,8
		Ž	109	10,5	8,3	9,6	10,3
C81	Hodgkinova bolezen Hodgkin's disease	M	36	3,5	3,1	3,4	3,5
		Ž	30	2,9	2,8	2,8	2,9
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	153	15,1	9,2	12,9	15,3
		Ž	131	12,7	5,9	8,3	9,9
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	67	6,6	3,6	5,5	6,8
		Ž	60	5,8	2,4	3,6	4,4
C91–C95	Levkemije Leukaemias	M	129	12,7	8,1	11,0	12,9
		Ž	109	10,5	4,9	6,7	8,0

* SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2010.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2010.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	12896	12101	93,8	750	5,8	45	0,3
		M	6885	6489	94,2	374	5,4	22	0,3
		Ž	6011	5612	93,4	376	6,3	23	0,4
C00	Ustnica Lip	M	16	16	100	0	0	0	0
		Ž	8	8	—	0	—	0	—
C01	Baza jezika Base of tongue	M	11	11	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	28	28	100	0	0	0	0
		Ž	12	12	—	0	—	0	—
C03	Dlesen Gum	M	6	6	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	31	31	100	0	0	0	0
		Ž	6	5	—	1	—	0	—
C05	Nebo Palate	M	12	12	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	8	—	0	—	0	—
		Ž	8	8	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	5	5	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	5	5	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C09	Tonzila Tonsil	M	29	29	100	0	0	0	0
		Ž	9	9	—	0	—	0	—
C10	Orofarinks Oropharynx	M	73	71	97,3	1	1,4	1	1,4
		Ž	8	8	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	11	11	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C12	Piriformni sinus Pyramiform sinus	M	29	29	100	0	0	0	0
		Ž	1	1	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	31	31	100	0	0	0	0
		Ž	0	0	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	63	58	92,1	4	6,3	1	1,6
		Ž	20	17	85,0	2	10,0	1	5,0
C16	Želodec Stomach	M	278	266	95,7	8	2,9	4	1,4
		Ž	190	178	93,7	10	5,3	2	1,1
C17	Tanko črevo Small intestine	M	23	22	95,7	1	4,3	0	0
		Ž	19	18	94,7	1	5,3	0	0
C18	Debelo črevo Colon	M	565	547	96,8	17	3,0	1	0,2
		Ž	434	417	96,1	10	2,3	7	1,6
C19	Rektosigmoidna zveza Rectosigmoid junction	M	95	95	100	0	0	0	0
		Ž	77	71	92,2	6	7,8	0	0
C20	Rektum Rectum	M	355	352	99,2	3	0,8	0	0
		Ž	183	173	94,5	10	5,5	0	0
C21	Anus in analni kanal Anus and anal canal	M	6	6	—	0	—	0	—
		Ž	9	9	—	0	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	106	57	53,8	48	45,3	1	0,9
		Ž	51	27	52,9	24	47,1	0	0
C23	Žolčnik Gallbladder	M	17	12	70,6	5	29,4	0	0
		Ž	45	26	57,8	19	42,2	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	41	21	51,2	20	48,8	0	0
		Ž	53	25	47,2	28	52,8	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti							
				Število Number	%*	Število Number	%*	Število Number	%*						
										Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
										Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	154	81	52,6	73	47,4	0	0						
		Ž	171	74	43,3	93	54,4	4	2,3						
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	1	1	—	0	—	0	—						
		Ž	3	2	—	1	—	0	—						
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	4	4	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C31	Obnosni sinusi Accessory sinuses	M	8	8	—	0	—	0	—						
		Ž	4	3	—	1	—	0	—						
C32	Grlo Larynx	M	112	112	100	0	0	0	0						
		Ž	8	8	—	0	—	0	—						
C33	Sapnik Trachea	M	5	5	—	0	—	0	—						
		Ž	4	4	—	0	—	0	—						
C34	Sapnica in pljuča Bronchus and lung	M	853	789	92,5	60	7,0	4	0,5						
		Ž	383	346	90,3	37	9,7	0	0						
C37	Timus Thymus	M	1	1	—	0	—	0	—						
		Ž	1	1	—	0	—	0	—						
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	6	1	—	5	—	0	—						
		Ž	2	1	—	1	—	0	—						
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—						
		Ž	0	0	—	0	—	0	—						
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	6	6	—	0	—	0	—						
		Ž	4	4	—	0	—	0	—						
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	1	1	—	0	—	0	—						
		Ž	4	4	—	0	—	0	—						
C43	Malignni melanom kože Malignant melanoma of skin	M	229	229	100	0	0	0	0						
		Ž	240	240	100	0	0	0	0						
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1043	1037	99,4	6	0,6	0	0						
		Ž	1058	1056	99,8	2	0,2	0	0						
C45	Mezoteliom Mesothelioma	M	25	25	100	0	0	0	0						
		Ž	8	8	—	0	—	0	—						
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	—	0	—	0	—						
		Ž	1	1	—	0	—	0	—						
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	—	0	—	0	—						
		Ž	0	0	—	0	—	0	—						
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	1	1	—	0	—	0	—						
		Ž	15	15	100	0	0	0	0						
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	17	17	100	0	0	0	0						
		Ž	22	22	100	0	0	0	0						
C50	Dojka Breast	M	12	11	—	1	—	0	—						
		Ž	1255	1236	98,5	14	1,1	5	0,4						
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—						
		Ž	55	55	100	0	0	0	0						
C52	Nožnica Vagina	M	—	—	—	—	—	—	—						
		Ž	4	4	—	0	—	0	—						
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—						
		Ž	142	142	100	0	0	0	0						
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—						
		Ž	324	324	100	0	0	0	0						
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—						
		Ž	11	9	—	2	—	0	—						
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—						
		Ž	172	162	94,2	9	5,2	1	0,6						

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–
		Ž	4	3	–	1	–	0	–
C58	Posteljica Placenta	M	–	–	–	–	–	–	–
		Ž	0	0	–	0	–	0	–
C60	Penis Penis	M	12	12	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C61	Prostata Prostate	M	1267	1218	96,1	44	3,5	5	0,4
		Ž	–	–	–	–	–	–	–
C62	Modo Testis	M	104	104	100	0	0	0	0
		Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	3	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	223	209	93,7	13	5,8	1	0,4
		Ž	99	84	84,8	15	15,2	0	0
C65	Ledvični meh Renal pelvis	M	19	18	94,7	1	5,3	0	0,0
		Ž	14	13	–	1	–	0	–
C66	Sečevod Ureter	M	7	7	–	0	–	0	–
		Ž	9	8	–	1	–	0	–
C67	Sečni mehur Bladder	M	202	192	95,0	7	3,5	3	1,5
		Ž	71	66	93,0	4	5,6	1	1,4
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	2	–	0	–	0	–
		Ž	2	2	–	0	–	0	–
C69	Oklo in očesni adnexa Eye and adnexa	M	8	8	–	0	–	0	–
		Ž	10	9	–	1	–	0	–
C70	Meninge Meninges	M	3	3	–	0	–	0	–
		Ž	2	2	–	0	–	0	–
C71	Možgani Brain	M	82	72	87,8	10	12,2	0	0
		Ž	73	64	87,7	9	12,3	0	0
C72	Hrbtini mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C73	Ščitnica Thyroid gland	M	39	39	100	0	0	0	0
		Ž	109	108	99,1	0	0	1	0,9
C74	Nadledvična žleza Adrenal gland	M	3	3	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	4	–	1	–	0	–
		Ž	34	18	52,9	16	47,1	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	28	26	92,9	2	7,1	0	0
		Ž	17	17	100	0	0	0	0
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	51	26	51,0	25	49,0	0	0
		Ž	53	24	45,3	28	52,8	1	1,9
C79	Metastaze, drugje Metastases of other sites	M	19	12	63,2	7	36,8	0	0
		Ž	19	11	57,9	8	42,1	0	0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	47	34	72,3	12	25,5	1	2,1
		Ž	47	26	55,3	21	44,7	0	0
C81	Hodgkinova bolezen Hodgkin's disease	M	36	36	100	0	0	0	0
		Ž	30	30	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	28	28	100	0	0	0	0
		Ž	29	29	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	106	106	100	0	0	0	0
		Ž	69	69	100	0	0	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	14	14	—	0	—	0	—
		Ž	23	23	100	0	0	0	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	5	5	—	0	—	0	—
		Ž	10	10	—	0	—	0	—
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	67	67	100	0	0	0	0
		Ž	60	60	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	8	8	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	57	57	100	0	0	0	0
		Ž	47	47	100	0	0	0	0
C92	Mieločna levkemija Myeloid leukaemia	M	46	46	100	0	0	0	0
		Ž	45	45	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	4	4	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	12	12	—	0	—	0	—
		Ž	7	7	—	0	—	0	—
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	54	54	100	0	0	0	0
		Ž	64	64	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	52	52	100	0	0	0	0
		Ž	84	84	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	0	0	—	0	—	0	—
		Ž	108	108	100	0	0	0	0
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	—	—	—	—	—	—	—
		Ž	957	957	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	138	138	100	0	0	0	0
		Ž	41	41	100	0	0	0	0
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	26	26	100	0	0	0	0
		Ž	43	42	97,7	1	2,3	0	0,0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	51	51	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	3	0	—	3	—	0	—
		Ž	7	2	—	4	—	1	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	104	0	0	0	3	8	18	23	21	17	7	5	1	0	0	0	1	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	223	0	0	0	0	0	0	1	4	3	12	25	32	36	39	33	18	20
		Ž	99	0	1	0	0	0	2	0	2	1	3	8	6	12	5	17	17	25
C65	Ledvični meh Renal pelvis	M	19	0	0	0	0	0	0	0	0	0	1	0	2	3	2	6	4	1
		Ž	14	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	2	7
C66	Sečevod Ureter	M	7	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	1
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	2	0	1	2	3	1
C67	Sečni mehur Bladder	M	202	0	0	0	0	0	1	0	0	3	1	7	20	20	32	36	37	45
		Ž	71	0	0	0	0	0	0	0	0	0	1	3	6	4	6	12	11	28
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C69	Oklo in očesni adneksi Eye and adnexa	M	8	1	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	2
		Ž	10	1	0	0	0	0	0	0	0	0	0	1	1	3	0	2	2	0
C70	Meninge Meninges	M	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
C71	Možgani Brain	M	82	0	1	0	2	0	1	5	3	3	11	6	11	9	11	8	8	3
		Ž	73	1	1	0	0	0	0	4	4	4	2	5	9	7	12	11	5	8
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	3	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	39	0	0	1	0	0	1	5	5	3	4	3	4	4	1	4	2	2
		Ž	109	0	0	2	3	3	9	6	8	13	9	10	13	13	9	5	2	4
C74	Nadledvična žleza Adrenal gland	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	1	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0
		Ž	34	0	0	0	0	0	0	0	1	1	0	0	0	0	1	5	3	23
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	28	0	0	0	0	0	0	0	1	1	1	3	3	4	3	5	3	4
		Ž	17	0	0	0	0	0	0	0	0	1	0	0	5	3	4	1	1	2
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	51	0	0	0	0	0	0	0	0	0	0	1	8	1	6	16	6	13
		Ž	53	0	0	0	0	0	0	0	0	0	0	3	2	1	2	3	12	30
C79	Metastaze, drugje Metastases of other sites	M	19	0	0	0	0	0	0	0	0	0	0	1	0	3	2	4	4	5
		Ž	19	0	0	0	0	0	0	1	0	0	0	1	2	2	2	3	3	5
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	47	0	0	0	0	0	0	1	0	1	3	4	6	7	3	8	8	6
		Ž	47	0	0	0	0	0	0	0	0	1	1	3	4	4	4	4	14	12
C81	Hodgkinova bolezen Hodgkin's disease	M	36	0	0	2	2	4	2	7	3	2	1	2	3	3	3	0	1	1
		Ž	30	0	1	2	3	2	4	0	4	0	2	4	0	1	0	1	1	5
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	28	0	0	0	0	0	0	1	2	1	3	3	6	2	2	3	1	4
		Ž	29	0	0	0	0	0	0	0	1	1	1	2	5	3	5	8	1	2
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	106	0	2	0	3	0	4	2	2	6	6	13	11	9	18	14	16	16
		Ž	69	0	0	0	2	1	1	1	1	1	4	7	5	3	9	14	20	
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	14	0	1	0	0	0	0	0	0	1	1	0	0	2	4	2	3	3
		Ž	23	0	0	0	0	0	0	1	0	3	1	1	0	5	2	3	5	2
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2
		Ž	10	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	3	5

Nadaljevanje →

Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	67	0	0	0	0	0	0	0	0	0	2	9	7	6	7	14	8	14
		Ž	60	0	0	0	0	0	0	0	1	0	3	3	5	4	9	8	13	14
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	8	1	2	0	1	1	1	0	0	0	0	0	1	0	0	0	0	1
		Ž	4	1	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	57	0	0	0	0	0	0	0	0	1	2	4	8	7	8	7	12	8
		Ž	47	0	0	0	0	0	0	0	0	0	0	3	5	2	4	6	8	19
C92	Mieločna levkemija Myeloid leukaemia	M	46	1	0	0	0	1	0	1	1	7	0	3	4	6	6	9	7	
		Ž	45	0	0	0	1	2	0	0	2	1	3	3	0	3	8	6	5	11
C93	Monocitna levkemija Monocytic leukaemia	M	4	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	12	0	0	0	0	0	0	0	1	1	0	1	2	1	4	1	0	1
		Ž	7	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	3	2
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	54	0	0	0	0	0	0	2	0	2	1	2	7	7	9	3	6	15
		Ž	64	0	0	0	3	2	0	5	0	1	1	1	2	5	6	10	6	22

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
D03	Melanom, in situ Melanoma, in situ	M	52	0	0	0	0	0	1	0	2	5	4	3	4	7	6	8	5	7
		Ž	84	0	0	0	0	1	1	8	12	5	4	5	8	9	3	10	7	11
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	108	0	0	0	0	0	1	1	3	6	10	23	17	19	16	4	6	2
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	957	0	0	0	2	86	195	210	162	121	75	39	27	23	7	5	2	3
D09.0	Sečni mehur, in situ Bladder, in situ	M	138	0	0	0	0	0	0	0	2	2	4	15	15	28	14	23	17	18
		Ž	41	0	0	0	0	0	0	0	0	1	3	5	7	3	5	10	7	
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	26	0	0	0	0	1	0	1	1	0	1	1	1	3	4	9	4	0
		Ž	43	0	0	0	0	2	0	0	2	1	3	4	8	6	3	5	4	5
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	51	0	0	0	0	1	3	5	6	5	8	2	6	6	4	2	2	1
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	3	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
		Ž	7	1	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2010.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2010.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00–C06	Vse lokacije All sites	M+Ž	629,3	10,5	9,9	8,5	27,8	26,3	48,7	97,9	127,2	224,5	361,9	588,9	945,5	1394,1	1840,1	2171,3	2421,1	2513,0	39,4
		M	678,5	11,2	12,8	6,2	22,4	23,7	46,3	81,7	103,7	159,3	298,4	567,8	1093,6	1717,8	2454,9	3022,3	3335,0	3595,3	48,1
		Ž	581,0	9,8	6,8	11,0	33,5	29,2	51,3	115,9	153,0	293,2	428,0	610,8	791,3	1081,4	1305,4	1508,5	1862,7	2087,6	32,1
C00	Ustnica Lip	M	1,6	0	0	0	0	0	0	0	0	0	0	0	2,6	1,7	4,4	5,3	14,5	21,5	0,1
		Ž	0,8	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	6,1	4,4	3,4	0,0
C01	Baza jezika Base of tongue	M	1,1	0	0	0	0	0	0	0	0	0	0	1,3	6,5	1,7	2,2	5,3	0	4,3	0,1
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	1,3	0	0	1,9	0	2,2	3,4	0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	2,8	0	0	0	0	0	0	0	0	1,3	6,3	6,3	3,9	7,0	6,7	7,9	10,9	4,3	0,2
		Ž	1,2	0	0	0	0	0	0	1,3	1,4	0	1,3	0	1,4	0	5,8	2,0	0	6,7	0,1
C03	Dlesen Gum	M	0,6	0	0	0	0	0	0	0	0	0	0	1,3	0	1,7	2,2	5,3	3,6	0	0,1
		Ž	0,5	0	0	0	0	0	0	0	0	1,3	0	0	0	0	1,9	0	0	5,1	0,0
C04	Ustno dno Floor of mouth	M	3,1	0	0	0	0	0	0	0	1,3	1,3	5,0	6,3	13,0	7,0	8,9	2,6	3,6	0	0,2
		Ž	0,6	0	0	0	0	0	0	0	0	2,7	0	0	0	1,7	1,9	0	0	3,4	0,0
C05	Nebo Palate	M	1,2	0	0	0	0	0	0	0	0	0	0	1,3	2,6	7,0	6,7	2,6	0	4,3	0,1
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	0	1,7	0	0	0	0	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	0,8	0	0	0	0	0	0	0	0	1,3	0	1,3	2,6	1,7	4,4	0	3,6	0	0,1
		Ž	0,8	0	0	0	0	0	0	0	0	0	1,3	1,3	0	1,7	1,9	2,0	4,4	1,7	0,0
C07	Parotidna žleza Parotid gland	M	0,5	0	0	0	0	0	0	0	0	0	0	2,5	2,6	0	2,2	0	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	3,4	0	0	2,2	0	0,0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,5	0	0	0	0	0	0	0	0	0	0	1,3	2,6	0	2,2	2,6	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	2,2	1,7	0,0
C09	Tonzila Tonsil	M	2,9	0	0	0	0	0	0	0	0	2,5	2,5	7,6	9,1	8,7	4,4	5,3	10,9	0	0,2
		Ž	0,9	0	0	0	0	0	0	0	0	0	2,6	1,3	0	3,4	0	6,1	2,2	0	0,1
C10	Orofarinks Oropharynx	M	7,2	0	0	0	0	0	0	0	0	0	8,8	7,6	33,7	20,9	15,5	26,3	10,9	8,6	0,6
		Ž	0,8	0	0	0	0	0	0	0	0	1,3	0	0	2,7	3,4	1,9	2,0	0	1,7	0,1
C11	Nazofarinks Nasopharynx	M	1,1	0	0	0	0	0	0	0	1,3	1,3	2,5	2,5	2,6	0	4,4	2,6	0	0	0,1
		Ž	0,4	2,0	0	0	0	0	0	0	0	1,3	0	1,3	1,4	0	0	0	0	0	0,0
C12	Piriformni sinus Pyiform sinus	M	2,9	0	0	0	0	0	0	0	0	2,5	1,3	1,3	10,4	15,6	8,9	2,6	3,6	8,6	0,2
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,7	0	0	0	0	0,0
C13	Hipofarinks Hypopharynx	M	3,1	0	0	0	0	0	0	0	0	1,3	5,0	3,8	2,6	7,0	11,1	21,0	7,3	8,6	0,3
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C15	Požiralnik Oesophagus	M	6,2	0	0	0	0	0	0	0	0	1,3	3,8	11,4	14,3	12,2	20,0	21,0	29,0	30,0	0,4
		Ž	1,9	0	0	0	0	0	0	0	0	0	0	0	2,7	1,7	1,9	8,2	13,3	10,1	0,1
C16	Želodec Stomach	M	27,4	0	0	0	0	0	0	1,2	1,3	5,1	12,5	19,0	32,4	59,1	84,3	128,8	130,5	278,9	1,7
		Ž	18,4	0	0	0	0	0	0	1,3	4,2	5,4	15,7	10,6	14,9	21,8	28,9	40,9	93,0	102,9	0,7
C17	Tanko črevo Small intestine	M	2,3	0	0	0	0	0	0	0	0	1,3	1,3	3,8	1,3	13,9	4,4	7,9	7,3	8,6	0,2
		Ž	1,8	0	0	0	0	0	0	0	0	2,7	2,6	1,3	2,7	0	3,9	6,1	6,6	6,7	0,1
C18	Debelo črevo Colon	M	55,7	0	0	0	0	0	1,3	0	2,6	7,6	12,5	55,8	98,6	166,9	206,2	226,0	308,1	283,2	3,9
		Ž	42,0	0	0	0	0	0	0	0	2,8	4,0	9,1	41,0	63,5	102,4	115,7	129,0	144,0	160,2	2,3

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	9,4	0	0	0	0	0	0	0	0	1,3	2,5	11,4	14,3	17,4	53,2	44,7	43,5	38,6	0,7
		Ž	7,4	0	0	0	0	0	0	1,3	0	2,7	1,3	9,3	12,2	15,1	17,4	16,4	31,0	28,7	0,4
C20	Rektum Rectum	M	35,0	0	0	0	0	0	0	1,2	2,6	5,1	15,0	36,8	67,5	97,4	159,7	134,0	159,5	137,3	2,6
		Ž	17,7	0	0	0	1,6	0	0	4,2	5,4	5,2	21,2	35,1	25,2	40,5	47,1	70,9	64,1	0,9	
C21	Anus in analni kanal Anus and anal canal	M	0,6	0	0	0	0	0	0	0	0	0	1,3	0	2,6	3,5	0	2,6	0	0	0,0
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	0	1,4	3,4	0	2,0	4,4	5,1	0,0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	10,4	3,7	0	0	0	0	0	0	0	2,5	5,0	8,9	14,3	26,1	46,6	73,6	39,9	21,5	0,9
		Ž	4,9	0	0	0	0	0	0	0	0	0	1,3	1,3	5,4	6,7	11,6	18,4	31,0	20,2	0,2
C23	Žolčnik Gallbladder	M	1,7	0	0	0	0	0	0	0	0	0	0	1,3	3,9	1,7	8,9	5,3	3,6	21,5	0,1
		Ž	4,3	0	0	0	0	0	0	0	0	0	1,3	2,6	5,4	5,0	7,7	14,3	22,1	23,6	0,2
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	4,0	0	0	0	0	0	0	0	0	0	6,3	2,5	1,3	7,0	6,7	15,8	36,3	42,9	0,2
		Ž	5,1	0	0	0	0	0	0	0	0	1,3	0	5,3	1,4	5,0	13,5	10,2	22,1	37,1	0,2
C25	Trebušna slinavka Pancreas	M	15,2	0	0	0	0	0	0	0	6,4	1,3	6,3	10,1	24,6	27,8	62,1	68,3	83,4	98,7	1,0
		Ž	16,5	0	0	0	0	0	0	1,3	0	1,3	2,6	9,3	10,8	20,1	40,5	45,0	68,7	111,3	0,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,1	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	1,4	1,3	0	0	0	0	0	0	0	0	1,7	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,4	0	0	0	0	0	0	0	0	1,3	0	0	1,3	1,7	0	2,6	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	1,7	0,0
C31	Obnosni sinusi Accessory sinuses	M	0,8	0	0	0	0	0	0	1,2	0	1,3	0	0	0	3,5	2,2	0	3,6	8,6	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,2	3,4	0,0
C32	Grlo Larynx	M	11,0	0	0	0	0	0	0	0	0	6,4	10,0	15,2	20,8	36,5	42,1	44,7	32,6	21,5	0,9
		Ž	0,8	0	0	0	0	0	0	0	0	2,7	1,3	2,6	1,4	0	3,9	0	0	0	0,1
C33	Sapnik Trachea	M	0,5	0	0	0	0	0	0	0	0	0	0	0	3,9	1,7	0	2,6	0	0	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	1,7	0	2,0	0	1,7	0,0
C34	Sapnica in pljuča Bronchus and lung	M	84,1	0	0	0	0	1,3	0	3,8	3,8	27,6	81,1	175,1	278,2	241,7	394,2	409,6	399,0	6,0	
		Ž	37,0	0	0	0	0	0	0	0	8,1	22,2	43,6	87,8	73,9	69,4	94,2	128,5	131,5	2,0	
C37	Timus Thymus	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,7	0	0	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0,0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,6	0	0	0	0	0	1,2	0	0	0	0	0	1,7	0	5,3	0	8,6	0,0	
		Ž	0,2	0	0	0	0	1,4	0	0	0	0	0	0	0	0	2,0	0	0	0	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,6	0	0	1,9	0	2,6	2,4	0	0	0	0	1,3	0	0	0	0	0	0	0,0
		Ž	0,4	0	0	2,0	0	0	1,3	0	0	0	0	1,4	0	0	2,0	0	0	0	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,1	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,4	0	0	0	1,6	0	0	1,4	0	2,6	0	0	0	0	0	0	0	0	0
C43	Malignni melanom kože Malignant melanoma of skin	M	22,6	0	0	3,7	0	3,9	8,4	16,6	19,1	26,3	21,5	29,8	45,2	82,1	68,3	79,8	72,9	1,6	
		Ž	23,2	0	0	2,0	1,6	12,8	20,0	14,0	21,5	20,9	29,1	23,0	35,3	50,1	61,4	48,7	57,3	1,5	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	102,8	0	0	0	0	5,1	7,2	11,5	33,1	37,6	72,2	107,7	198,2	354,8	457,3	688,8	815,2	6,4	
		Ž	102,3	0	0	0	0	4,3	6,7	18,2	55,1	67,9	67,4	98,6	156,2	216,0	323,4	378,7	482,3	5,1	
C45	Mezoteliom Mesothelioma	M	2,5	0	0	0	0	0	0	0	0	0	0	7,8	7,0	8,9	15,8	10,9	8,6	0,2	
		Ž	0,8	0	0	2,0	0	0	0	0	0	0	0	1,4	3,4	0	4,1	2,2	1,7	0,1	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,7	0,0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,7	0	0	0	0	0,0	
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	2,7	1,7	3,9	2,0	8,9	8,4	0,1	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	1,7	0	0	1,9	0	0	0	0	3,8	1,3	0	2,6	3,5	2,2	0	14,5	12,9	0,1	
		Ž	2,1	0	2,2	0	0	0	1,4	1,3	1,3	1,3	4,1	3,4	3,9	2,0	6,6	10,1	0,1		
C50	Dojka Breast	M	1,2	0	0	0	0	0	0	0	0	0	0	7,8	1,7	4,4	5,3	0	4,3	0,1	
		Ž	121,3	0	0	0	1,6	2,8	40,0	40,7	91,4	155,3	191,7	201,2	302,2	318,2	227,2	259,1	234,4	7,9	
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	5,3	0	0	0	0	0	0	0	0	3,9	7,9	2,7	6,7	11,6	14,3	31,0	21,9	0,2	
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,4	0	0	2,0	4,4	0	0,0	
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	13,7	0	0	0	0	2,8	16,0	21,1	24,2	26,1	26,4	16,2	13,4	27,0	16,4	17,7	8,4	0,9	
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	31,3	0	0	0	0	1,4	0	1,4	9,4	23,5	34,4	45,9	92,4	94,5	88,0	108,5	69,1	2,0	
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	1,1	0	0	0	0	0	0	0	0	0	1,3	2,7	1,7	0	8,2	2,2	3,4	0,1	
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	16,6	0	0	5,9	3,2	1,4	2,7	5,6	9,4	19,6	18,5	37,8	31,9	40,5	49,1	31,0	30,4	1,1	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	1,7	0	2,0	2,2	1,7	0,0	
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C60	Penis Penis	M	1,2	0	0	0	0	0	0	0	0	0	3,8	1,3	5,2	0	5,3	0	12,9	0,1	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C61	Prostata Prostate	M	124,9	0	0	0	0	0	0	0	0	1,3	15,0	60,8	177,7	386,0	636,4	720,1	656,1	450,5	10,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	10,2	0	0	0	5,6	11,8	23,2	27,6	26,9	21,7	8,8	6,3	1,3	0	0	0	0	4,3	0,7
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	0	3,6	4,3	0,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	22,0	0	0	0	0	0	1,2	5,1	3,8	15,0	31,7	41,5	62,6	86,5	86,7	65,3	85,8	1,7	
		Ž	9,6	0	2,3	0	0	0	2,8	0	2,8	1,3	3,9	10,6	8,1	20,1	9,6	34,8	37,7	42,2	0,5
C65	Ledvični meh Renal pelvis	M	1,9	0	0	0	0	0	0	0	0	1,3	0	2,6	5,2	4,4	15,8	14,5	4,3	0,1	
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	0	1,7	1,9	6,1	4,4	11,8	0,0	
C66	Sečevod Ureter	M	0,7	0	0	0	0	0	0	0	0	0	0	1,3	3,5	2,2	2,6	3,6	4,3	0,0	
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	2,7	0	1,9	4,1	6,6	1,7	0,0	
C67	Sečni mehur Bladder	M	19,9	0	0	0	0	1,3	0	0	3,8	1,3	8,9	25,9	34,8	71,0	94,6	134,1	193,1	1,2	
		Ž	6,9	0	0	0	0	0	0	0	0	1,3	4,0	8,1	6,7	11,6	24,6	24,4	47,2	0,3	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	1,7	0	2,6	0	0	0,0	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	0	1,7	0,0	
C69	Okno in očesni adneksi Eye and adnexa	M	0,8	1,9	0	0	0	0	0	0	0	1,3	1,3	1,3	1,7	2,2	0	0	8,6	0,0	
		Ž	1,0	2,0	0	0	0	0	0	0	0	0	1,3	1,4	5,0	0	4,1	4,4	0	0,1	
C70	Meninge Meninges	M	0,3	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	2,6	0	0	0,0	
		Ž	0,2	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,2	0	0,0	
C71	Možgani Brain	M	8,1	0	2,1	0	3,7	0	1,3	6,0	3,8	3,8	13,8	7,6	14,3	15,6	24,4	21,0	29,0	12,9	0,6
		Ž	7,1	2,0	2,3	0	0	0	0	5,3	5,6	5,4	2,6	6,6	12,2	11,8	23,1	22,5	11,1	13,5	0,5
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,3	2,0	0	0	1,6	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0,0
C73	Ščitnica Thyroid gland	M	3,8	0	0	2,1	0	0	1,3	6,0	6,4	3,8	5,0	3,8	5,2	7,0	2,2	10,5	7,3	8,6	0,3
		Ž	10,5	0	0	4,4	5,9	4,9	12,8	8,0	11,2	17,5	11,7	13,2	17,6	21,8	17,4	10,2	4,4	6,7	0,8
C74	Nadledvična žleza Adrenal gland	M	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	0	2,2	0	3,6	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,5	1,9	0	0	0	0	0	0	0	0	0	0	0	1,7	2,2	5,3	0	0	0,1
		Ž	3,3	0	0	0	0	0	0	0	1,4	1,3	0	0	0	0	1,9	10,2	6,6	38,8	0,1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	2,8	0	0	0	0	0	0	0	1,3	1,3	1,3	3,8	3,9	7,0	6,7	13,1	10,9	17,2	0,2
		Ž	1,6	0	0	0	0	0	0	0	0	1,3	0	0	6,8	5,0	7,7	2,0	2,2	3,4	0,1

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C78	Metastaze dihal in prebavil	M	5,0	0	0	0	0	0	0	0	0	0	0	1,3	10,4	1,7	13,3	42,0	21,8	55,8	0,3
	Metastases of respiratory and digestive organs	Ž	5,1	0	0	0	0	0	0	0	0	0	0	4,0	2,7	1,7	3,9	6,1	26,6	50,6	0,1
C79	Metastaze, druge	M	1,9	0	0	0	0	0	0	0	0	0	0	1,3	0	5,2	4,4	10,5	14,5	21,5	0,1
	Metastases of other sites	Ž	1,8	0	0	0	0	0	0	1,3	0	0	0	1,3	2,7	3,4	3,9	6,1	6,6	8,4	0,1
C80	Maligna neoplazma brez opredeljenega mesta	M	4,6	0	0	0	0	0	0	1,2	0	1,3	3,8	5,1	7,8	12,2	6,7	21,0	29,0	25,7	0,3
	Malignant neoplasm without specification of site	Ž	4,5	0	0	0	0	0	0	0	0	1,3	1,3	4,0	5,4	6,7	7,7	8,2	31,0	20,2	0,2
C81	Hodgkinova bolezen	M	3,5	0	0	4,1	3,7	5,9	2,6	8,4	3,8	2,5	1,3	2,5	3,9	5,2	6,7	0	3,6	4,3	0,3
	Hodgkin's disease	Ž	2,9	0	2,3	4,4	5,9	3,2	5,7	0	5,6	0	2,6	5,3	0	1,7	0	2,0	2,2	8,4	0,2
C82	Folikularni ne-Hodgkinov limfom	M	2,8	0	0	0	0	0	0	1,2	2,6	1,3	3,8	3,8	7,8	3,5	4,4	7,9	3,6	17,2	0,2
	Follicular non-Hodgkin's lymphoma	Ž	2,8	0	0	0	0	0	0	0	1,4	1,3	1,3	2,6	6,8	5,0	9,6	16,4	2,2	3,4	0,2
C83	Difuzni ne-Hodgkinov limfom	M	10,4	0	4,3	0	0	4,4	0	4,8	2,6	2,5	7,5	7,6	16,9	19,1	20,0	47,3	50,8	68,6	0,7
	Diffuse non-Hodgkin's lymphoma	Ž	6,7	0	0	0	0	3,2	1,4	1,3	1,4	1,3	1,3	5,3	9,5	8,4	5,8	18,4	31,0	33,7	0,3
C84	Limfomi celic T in kožni limfom celic T	M	1,4	0	2,1	0	0	0	0	0	0	0	1,3	1,3	0	0	4,4	10,5	7,3	12,9	0,1
	Peripheral and cutaneous T-cell lymphomas	Ž	2,2	0	0	0	0	0	0	1,3	0	4,0	1,3	1,3	0	8,4	3,9	6,1	11,1	3,4	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	0,5	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	5,3	0	8,6	0,0
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	1,9	0	6,6	8,4	0,0
C88	Maligne imunoproliferativne bolezni	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Malignant immunoproliferative diseases	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,1	0	0	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	6,6	0	0	0	0	0	0	0	0	0	2,5	11,4	9,1	10,4	15,5	36,8	29,0	60,1	0,4
	Multiple myeloma and malignant plasma cell neoplasms	Ž	5,8	0	0	0	0	0	0	0	1,4	0	3,9	4,0	6,8	6,7	17,4	16,4	28,8	23,6	0,3
C91.0	Limfatična levkemija, akutna	M	0,8	1,9	4,3	0	1,9	1,5	1,3	0	0	0	0	0	1,3	0	0	0	0	4,3	0,1
	Lymphoblastic leukaemia, acute	Ž	0,4	2,0	0	0	2,0	0	0	0	0	0	0	0	0	1,7	0	2,0	0	0	0,0
C91.1 – C91.9	Limfatična levkemija, druga	M	5,6	0	0	0	0	0	0	0	0	1,3	2,5	5,1	10,4	12,2	17,7	18,4	43,5	34,3	0,3
	Lymphoid leukaemia, other	Ž	4,5	0	0	0	0	0	0	0	0	0	0	4,0	6,8	3,4	7,7	12,3	17,7	32,0	0,2
C92	Mieloična levkemija	M	4,5	1,9	0	0	0	1,3	0	1,3	1,3	8,8	0	3,9	7,0	13,3	15,8	32,6	30,0	0,3	
	Myeloid leukaemia	Ž	4,3	0	0	0	2,0	3,2	0	0	2,8	1,3	3,9	4,0	0	5,0	15,4	12,3	11,1	18,5	0,2

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C93	Monocitna levkemija Monocytic leukaemia	M	0,4	0	0	0	0	0	0	0	0	0	1,3	0	2,6	0	0	2,6	0	0	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,0	4,4	0	0,0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	1,2	0	0	0	0	0	0	0	1,3	1,3	0	1,3	2,6	1,7	8,9	2,6	0	4,3	0,1
		Ž	0,7	0	0	0	0	0	0	0	0	0	0	2,6	0	0	0	6,6	3,4	0,0	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	4,3	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	1,7	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	5,3	0	0	0	0	0	0	2,4	0	2,5	1,3	2,5	9,1	12,2	20,0	7,9	21,8	64,4	0,3
		Ž	6,2	0	0	0	5,9	3,2	0	6,7	0	1,3	1,3	1,3	2,7	8,4	11,6	20,5	13,3	37,1	0,3

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ Melanoma, in situ	M	5,1	0	0	0	0	0	1,3	0	2,6	6,4	5,0	3,8	5,2	12,2	13,3	21,0	18,1	30,0	0,4
		Ž	8,1	0	0	0	1,6	1,4	10,7	16,8	6,7	5,2	6,6	10,8	15,1	5,8	20,5	15,5	18,5	0,5	
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	10,4	0	0	0	0	1,4	1,3	4,2	8,1	13,1	30,4	23,0	31,9	30,9	8,2	13,3	3,4	0,8	
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	92,5	0	0	0	3,9	139,7	277,6	279,9	227,4	162,7	97,9	51,6	36,5	38,6	13,5	10,2	4,4	5,1	6,7
D09.0	Sečni mehur, in situ Bladder, in situ	M	13,6	0	0	0	0	0	0	2,6	2,5	5,0	19,0	19,5	48,7	31,0	60,4	61,6	77,2	0,9	
		Ž	4,0	0	0	0	0	0	0	0	0	1,3	4,0	6,8	11,8	5,8	10,2	22,1	11,8	0,2	
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	2,6	0	0	0	1,5	0	1,2	1,3	0	1,3	1,3	1,3	5,2	8,9	23,7	14,5	0	0,2	
		Ž	4,2	0	0	0	3,2	0	0	2,8	1,3	3,9	5,3	10,8	10,1	5,8	10,2	8,9	8,4	0,3	
D33.0 – D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	2,6	0	0	0	0	0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja Ovary, neopl. of uncertain behavior	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	4,9	0	0	0	1,6	4,3	6,7	8,4	6,7	10,4	2,6	8,1	10,1	7,7	4,1	4,4	1,7	0,4	
D43.0 – D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	0,3	0	2,1	0	0	0	0	0	0	0	0	0	0	0	2,2	0	0	4,3	0,0
		Ž	0,7	2,0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	2,0	2,2	5,1	0,0

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2010.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2010.

Statistična regija Statistical region	Spol Sex	Skupaj All sites C00–C96	Primarna lokacija (šifra MKB) Primary site (ICD code)											
			C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06*
Slovenija, skupaj Slovenia, total	M	6885	278	565	95	355	853	1043	12	–	–	1267	2417	–
	Ž	6011	190	434	77	183	383	1058	1255	142	324	–	1965	957
Pomurska	M	419	21	25	4	18	54	61	0	–	–	104	132	–
	Ž	337	23	22	7	15	13	73	50	5	15	–	114	59
Podravska	M	1018	52	85	9	55	141	112	1	–	–	198	365	–
	Ž	856	34	56	10	47	52	111	191	27	60	–	268	177
Koroška	M	257	19	24	8	21	38	35	0	–	–	55	57	–
	Ž	205	10	15	3	2	16	47	39	6	11	–	56	32
Savinjska	M	810	44	75	15	48	86	120	2	–	–	122	298	–
	Ž	695	19	62	10	16	45	122	132	21	45	–	223	79
Zasavska	M	143	7	10	3	17	22	13	0	–	–	12	59	–
	Ž	150	6	12	0	4	12	10	43	4	5	–	54	7
Spodnjeposavska	M	257	17	23	4	6	19	32	0	–	–	53	103	–
	Ž	191	7	11	5	6	12	25	35	7	12	–	71	27
Jugovzhodna Slovenija	M	539	20	53	13	22	57	80	1	–	–	112	181	–
	Ž	426	18	22	17	12	26	97	81	12	19	–	122	59
Osrednjeslovenska	M	1822	47	118	23	77	221	348	3	–	–	325	660	–
	Ž	1734	39	120	11	44	128	337	368	38	90	–	559	258
Gorenjska	M	704	19	62	5	36	98	101	3	–	–	149	231	–
	Ž	613	17	53	5	16	26	98	140	12	30	–	216	155
Notranjsko-kraška	M	170	5	10	4	6	19	22	1	–	–	31	72	–
	Ž	110	1	11	2	1	7	16	21	1	6	–	44	13
Goriška	M	370	12	49	4	24	45	44	0	–	–	60	132	–
	Ž	351	11	35	5	11	23	49	82	3	14	–	118	30
Obalno-kraška	M	376	15	31	3	25	53	75	1	–	–	46	127	–
	Ž	343	5	15	2	9	23	73	73	6	17	–	120	61

Opis šifer MKB/Description of the ICD code

- C16 Želodec
Stomach
- C18 Debelo črevo
Colon
- C19 Rektosigmoidna zveza
Rectosigmoid junction
- C20 Rektum
Rectum
- C34 Sapnica in pljuča
Bronchus and lung

- C44 Koža, razen melanoma
Skin, non-melanoma
- C50 Dojka
Breast
- C53 Maternični vrat
Cervix uteri
- C54 Maternično telo
Corpus uteri
- C61 Prostata
Prostate
- D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2010.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2010.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
			C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other
Slovenija, skupaj Slovenia, total	M	687,2	28,4	56,0	9,5	34,9	83,6	107,0	1,1	–	–	127,8	261,5	–
	Ž	466,7	13,4	32,5	5,7	13,7	28,7	78,2	105,1	13,2	25,9	–	179,5	99,0
Pomurska	M	705,9	35,2	43,3	5,7	29,4	86,3	106,6	0	–	–	181,2	249,0	–
	Ž	400,8	23,9	24,3	7,8	18,0	17,3	74,5	64,0	7,9	18,8	–	154,1	105,9
Podravska	M	630,9	33,3	53,6	5,8	31,9	86,4	72,0	0,6	–	–	123,8	232,6	–
	Ž	407,5	16,2	25,9	4,3	22,4	24,8	47,9	99,1	15,3	28,7	–	146,5	116,1
Koroška	M	705,4	55,9	68,6	24,7	56,0	102,0	104,2	0	–	–	141,8	163,5	–
	Ž	462,2	22,6	33,4	6,9	2,8	36,6	102,2	94,8	15,6	24,1	–	135,9	99,0
Savinjska	M	649,2	35,9	60,7	11,4	38,6	67,3	101,0	1,9	–	–	97,3	255,6	–
	Ž	449,6	11,1	36,0	5,4	10,4	26,6	76,9	92,7	14,5	31,0	–	170,3	63,3
Zasavska	M	627,1	31,5	42,5	11,5	74,7	92,3	62,4	0	–	–	53,0	271,1	–
	Ž	507,9	13,6	42,1	0	12,7	37,1	31,4	165,9	17,6	16,4	–	207,2	34,3
Spodnjeposavska	M	722,9	50,2	64,5	10,6	16,8	51,0	92,9	0	–	–	152,3	299,5	–
	Ž	441,3	16,8	23,1	11,8	14,3	26,7	57,6	85,1	18,7	26,2	–	178,4	82,6
Jugovzhodna Slovenija	M	799,0	31,4	76,1	18,6	32,9	83,8	121,3	1,0	–	–	169,4	290,1	–
	Ž	503,1	19,7	27,4	20,1	14,1	30,8	106,7	103,0	17,8	22,9	–	166,5	90,5
Osrednjeslovenska	M	733,7	19,2	46,9	9,7	30,6	87,6	142,9	1,1	–	–	132,7	300,2	–
	Ž	535,1	11,6	36,7	3,4	12,8	37,3	100,9	121,3	13,6	28,9	–	216,4	98,6
Gorenjska	M	714,0	19,8	62,3	4,6	36,1	98,2	104,5	2,2	–	–	153,2	261,3	–
	Ž	480,8	10,0	38,5	3,8	12,1	20,4	74,7	117,3	12,2	24,5	–	192,7	164,1
Notranjsko-kraška	M	635,0	19,6	37,8	16,0	22,1	69,4	84,6	2,5	–	–	113,7	288,1	–
	Ž	341,6	2,6	36,9	4,1	2,6	15,8	46,9	68,4	4,3	19,1	–	170,0	57,7
Goriška	M	583,5	18,6	73,5	6,4	37,0	69,6	71,9	0	–	–	96,0	220,4	–
	Ž	425,2	10,8	43,6	6,7	12,9	27,2	57,9	102,1	5,6	17,4	–	157,3	58,0
Obalno-kraška	M	654,1	27,3	52,4	5,4	44,9	91,7	131,3	2,0	–	–	81,6	232,9	–
	Ž	468,4	4,4	19,1	3,1	12,2	31,6	99,4	109,0	8,8	22,9	–	189,8	118,7

Opis šifer MKB/Description of the ICD code

C16 Želodec
Stomach
C18 Debelo črevo
Colon
C19 Rektosigmoidna zveza
Rectosigmoid junction
C20 Rektum
Rectum
C34 Sapnica in pljuča
Bronchus and lung

C44 Koža, razen melanoma
Skin, non-melanoma
C50 Dojka
Breast
C53 Maternični vrat
Cervix uteri
C54 Maternično telo
Corpus uteri
C61 Prostata
Prostate
D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

** Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

** Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																					
		C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
		H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	11518	583	78	1	15	0	30	0	31	0	0	0	73	2	436	8	40	0	962	2	166	0	
Small cell carcinoma	180	41	–	–	–	–	–	–	–	–	–	–	1	–	–	–	1	–	1	–	–	–	
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Squamous cell carcinoma	1392	53	76	–	12	–	30	–	31	–	–	–	52	–	2	–	–	–	–	–	–	–	
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Transitional cell carcinoma	289	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Adenocarcinoma	6008	160	–	–	–	–	–	–	–	–	–	–	18	–	406	2	22	–	948	–	165	–	
Other specified carcinomas	126	7	–	–	–	–	–	–	–	–	–	–	1	–	3	–	–	–	1	–	–	–	
Carcinoma, unspecified	102	159	1	1	2	–	–	–	–	–	–	–	1	2	11	5	–	–	10	2	1	–	
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant melanoma	492	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	1	–	–	–	
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified sarcomas	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant complex mixed and stromal tumors	62	2	1	–	–	–	–	–	–	–	–	–	–	13	–	15	–	1	–	–	–	–	
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Dysgerminoma and seminoma	62	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other malignant germ cell tumors	45	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Plasma cell tumors	115	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic lymphoid leukemia	77	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leukemia except chronic lymphoid	104	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant tumor, unspecified	12	9	–	–	1	–	–	–	–	–	–	–	–	–	1	1	–	–	–	–	–	–	

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11518	583	524	1	15	0	72	12	37	1	42	4	123	32	2	1	6	0	11	0	120	0
Small cell carcinoma	180	41	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1392	53	–	–	11	–	–	–	–	–	–	–	–	–	–	–	3	–	7	–	114	–
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	289	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6008	160	514	1	2	–	70	11	29	–	42	3	114	21	2	–	1	–	–	–	1	–
Other specified carcinomas	126	7	–	–	–	–	–	–	3	–	–	–	1	–	–	–	–	–	–	1	–	1
Carcinoma, unspecified	102	159	8	–	–	–	1	–	3	1	–	1	6	11	–	–	–	–	–	1	–	4
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	492	4	1	–	2	–	–	–	–	–	–	–	–	–	–	–	2	–	1	–	–	–
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	62	2	1	–	–	–	1	1	–	–	–	–	–	–	–	1	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	62	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	45	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	115	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	77	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	104	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	12	9	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C				
Vse vrste/All types	11518	583	157	5	3	0	0	0	12	0	1214	4	104	0	3	0	288	5	28	3	15	0				
Small cell carcinoma	180	41	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Squamous cell carcinoma	1392	53	–	–	–	–	–	–	11	–	–	–	–	–	–	–	–	–	–	–	–	–				
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Transitional cell carcinoma	289	2	–	–	1	–	–	–	–	–	3	–	–	–	1	–	–	–	27	1	14	–				
Adenocarcinoma	6008	160	144	2	1	–	–	–	–	–	1204	2	–	–	–	–	283	3	–	–	1	–				
Other specified carcinomas	126	7	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–				
Carcinoma, unspecified	102	159	1	3	–	–	–	–	–	–	5	1	–	–	–	–	1	1	–	2	–	–				
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant melanoma	492	4	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–				
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	1	–	1	–	–	–	–	–				
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified sarcomas	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant complex mixed and stromal tumors	62	2	4	–	1	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–				
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant gonadal stromal tumors	2	0	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Dysgerminoma and seminoma	62	0	2	–	–	–	–	–	–	–	–	–	60	–	–	–	–	–	–	–	–	–				
Other malignant germ cell tumors	45	1	3	–	–	–	–	–	–	–	–	–	42	–	–	–	–	–	–	–	–	–				
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–				
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Plasma cell tumors	115	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic lymphoid leukemia	77	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Leukemia except chronic lymphoid	104	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant tumor, unspecified	12	9	1	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	1	1	–	–				

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11518	583	254	4	3	1	17	0	5	0	136	0	3	0	143	4	3	0	1	0	14	8
Small cell carcinoma	180	41	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1392	53	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	289	2	240	1	2	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6008	160	3	–	1	–	–	–	–	–	–	–	–	–	142	3	2	–	–	–	6	7
Other specified carcinomas	126	7	–	–	–	–	–	–	–	–	–	–	–	–	1	1	–	–	–	–	–	–
Carcinoma, unspecified	102	159	6	3	–	1	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	1
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	492	4	–	–	–	–	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	3	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	1
Malignant complex mixed and stromal tumors	62	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	4
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	62	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	45	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	135	–	3	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1
Malignant meningioma	5	0	–	–	–	–	–	–	5	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	115	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	77	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	104	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–
Malignant tumor, unspecified	12	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																					
		C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88	
		H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11518	583	28	15	25	25	20	3	40	20	64	2	50	7	166	9	36	1	12	3	2	0	
Small cell carcinoma	180	41	1	–	–	2	1	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Squamous cell carcinoma	1392	53	19	9	1	–	2	1	3	–	–	–	–	–	–	–	–	–	–	–	–	–	
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Transitional cell carcinoma	289	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Adenocarcinoma	6008	160	7	4	19	13	10	–	20	10	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified carcinomas	126	7	–	–	1	–	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Carcinoma, unspecified	102	159	1	1	4	9	2	2	7	9	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant melanoma	492	4	–	–	–	–	1	–	5	1	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified sarcomas	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant complex mixed and stromal tumors	62	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Dysgerminoma and seminoma	62	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other malignant germ cell tumors	45	1	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	50	7	166	9	36	1	12	3	2	–	
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	64	2	–	–	–	–	–	–	–	–	–	–	
Plasma cell tumors	115	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic lymphoid leukemia	77	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leukemia except chronic lymphoid	104	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant tumor, unspecified	12	9	–	–	–	1	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
			C00–C96		C90		C91		C92		C93		C94		C95	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11518	583	115	12	95	21	77	14	8	0	18	1	1	3	102	16
Small cell carcinoma	180	41	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1392	53	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1691	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	289	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6008	160	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	126	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	102	159	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	492	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	12	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	62	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	29	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	62	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	45	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	138	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	266	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	64	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	115	12	115	12	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	77	17	–	–	77	17	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	104	21	–	–	18	4	77	14	8	–	–	–	1	3	–	–
Other lymphoreticular neoplasms	1	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Chronic myeloproliferative diseases	76	5	–	–	–	–	–	–	–	–	18	1	–	–	58	4
Myelodysplastic syndromes	43	12	–	–	–	–	–	–	–	–	–	–	–	–	43	12
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	12	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2010.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2010.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij											
				Omejen		Razširjen		Razsejan		Neznan					
				Število	%*	Število	%*	Število	%*	Število	%*				
				Stage				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*	Number	%*		
C00 – C80	Vse lokacije All sites	M+Ž	12017	6031	50,2	3564	29,7	2201	18,3	221	1,8				
		M	6425	3178	49,5	1943	30,2	1182	18,4	122	1,9				
C00	Ustnica Lip	M	16	16	100	0	0	0	0	0	0				
		Ž	8	8	—	0	—	0	—	0	—				
C01	Baza jezika Base of tongue	M	11	0	—	11	—	0	—	0	—				
		Ž	5	2	—	3	—	0	—	0	—				
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	28	5	17,9	23	82,1	0	0	0	0				
		Ž	12	3	—	9	—	0	—	0	—				
C03	Dlesen Gum	M	6	2	—	4	—	0	—	0	—				
		Ž	5	1	—	4	—	0	—	0	—				
C04	Ustno dno Floor of mouth	M	31	9	29,0	22	71,0	0	0	0	0				
		Ž	6	1	—	4	—	0	—	1	—				
C05	Nebo Palate	M	12	3	—	9	—	0	—	0	—				
		Ž	2	2	—	0	—	0	—	0	—				
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	3	—	5	—	0	—	0	—				
		Ž	8	4	—	4	—	0	—	0	—				
C07	Parotidna žleza Parotid gland	M	5	2	—	3	—	0	—	0	—				
		Ž	3	3	—	0	—	0	—	0	—				
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	5	1	—	4	—	0	—	0	—				
		Ž	3	3	—	0	—	0	—	0	—				
C09	Tonzila Tonsil	M	29	4	13,8	24	82,8	1	3,4	0	0				
		Ž	9	1	—	8	—	0	—	0	—				
C10	Orofarinks Oropharynx	M	72	7	9,7	59	81,9	5	6,9	1	1,4				
		Ž	8	1	—	7	—	0	—	0	—				
C11	Nazofarinks Nasopharynx	M	11	0	—	10	—	1	—	0	—				
		Ž	4	1	—	3	—	0	—	0	—				
C12	Piriformni sinus Pyriform sinus	M	29	3	10,3	25	86,2	1	3,4	0	0				
		Ž	1	0	—	1	—	0	—	0	—				
C13	Hipofarinks Hypopharynx	M	31	2	6,5	26	83,9	3	9,7	0	0				
		Ž	0	0	—	0	—	0	—	0	—				
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	—	0	—	0	—	0	—				
		Ž	0	0	—	0	—	0	—	0	—				
C15	Požiralnik Oesophagus	M	62	7	11,3	37	59,7	17	27,4	1	1,6				
		Ž	19	3	15,8	10	52,6	6	31,6	0	0				
C16	Želodec Stomach	M	274	50	18,2	115	42,0	105	38,3	4	1,5				
		Ž	188	32	17,0	80	42,6	72	38,3	4	2,1				
C17	Tanko črevo Small intestine	M	23	9	39,1	11	47,8	3	13,0	0	0				
		Ž	19	3	15,8	7	36,8	8	42,1	1	5,3				
C18	Debelo črevo Colon	M	564	136	24,1	315	55,9	103	18,3	10	1,8				
		Ž	427	81	19,0	260	60,9	79	18,5	7	1,6				
C19	Rektosigmoidna zveza Rectosigmoid junction	M	95	24	25,3	53	55,8	17	17,9	1	1,1				
		Ž	77	16	20,8	48	62,3	13	16,9	0	0				
C20	Rektum Rectum	M	355	73	20,6	212	59,7	61	17,2	9	2,5				
		Ž	183	34	18,6	100	54,6	40	21,9	9	4,9				
C21	Anus in analni kanal Anus and anal canal	M	6	0	—	5	—	0	—	1	—				
		Ž	9	1	—	4	—	3	—	1	—				
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	105	55	52,4	14	13,3	32	30,5	4	3,8				
		Ž	51	19	37,3	10	19,6	18	35,3	4	7,8				
C23	Žolčnik Gallbladder	M	17	3	17,6	5	29,4	9	52,9	0	0				
		Ž	45	6	13,3	13	28,9	25	55,6	1	2,2				
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	41	9	22,0	15	36,6	10	24,4	7	17,1				
		Ž	53	7	13,2	26	49,1	10	18,9	10	18,9				
C25	Trebušna slinavka Pancreas	M	154	9	5,8	50	32,5	87	56,5	8	5,2				
		Ž	167	13	7,8	67	40,1	80	47,9	7	4,2				
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	1	0	—	1	—	0	—	0	—				
		Ž	3	0	—	0	—	3	—	0	—				

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
Localized		Regional		Distant		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	4	2	—	2	—	0	—	0	—
		Ž	2	0	—	2	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	8	0	—	7	—	0	—	1	—
		Ž	4	0	—	2	—	1	—	1	—
C32	Grlo Larynx	M	112	61	54,5	50	44,6	1	0,9	0	0
		Ž	8	5	—	3	—	0	—	0	—
C33	Sapnik Trachea	M	5	2	—	1	—	2	—	0	—
		Ž	4	0	—	0	—	3	—	1	—
C34	Sapnica in pljuča Bronchus and lung	M	849	109	12,8	303	35,7	428	50,4	9	1,1
		Ž	383	66	17,2	93	24,3	219	57,2	5	1,3
C37	Timus Thymus	M	1	0	—	1	—	0	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	6	3	—	2	—	1	—	0	—
		Ž	2	0	—	0	—	2	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	6	2	—	2	—	2	—	0	—
		Ž	4	1	—	1	—	2	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	1	1	—	0	—	0	—	0	—
		Ž	4	2	—	2	—	0	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	229	162	70,7	57	24,9	8	3,5	2	0,9
		Ž	240	178	74,2	60	25,0	1	0,4	1	0,4
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1043	1024	98,2	15	1,4	3	0,3	1	0,1
		Ž	1058	1046	98,9	11	1,0	1	0,1	0	0
C45	Mezoteliom Mesothelioma	M	25	11	44,0	12	48,0	2	8,0	0	0
		Ž	8	3	—	4	—	0	—	1	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	1	0	—	1	—	0	—	0	—
		Ž	15	1	6,7	4	26,7	9	60,0	1	6,7
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	17	4	23,5	10	58,8	3	17,6	0	0
		Ž	22	10	45,5	9	40,9	3	13,6	0	0
C50	Dojka Breast	M	12	4	—	5	—	3	—	0	—
		Ž	1250	635	50,8	538	43,0	75	6,0	2	0,2
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	55	28	50,9	26	47,3	1	1,8	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	4	1	—	3	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	142	71	50,0	53	37,3	17	12,0	1	0,7
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	324	237	73,1	51	15,7	22	6,8	14	4,3
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	11	1	—	3	—	5	—	2	—
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	171	22	12,9	16	9,4	133	77,8	0	0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	4	1	—	0	—	3	—	0	—
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—	0	—
C60	Penis Penis	M	12	9	—	3	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1262	858	68,0	290	23,0	85	6,7	29	2,3
		Ž	—	—	—	—	—	—	—	—	—

Nadaljevanje →

Continued →

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
Localized		Regional		Distant		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C62	Modo Testis	M	104	64	61,5	30	28,8	10	9,6	0	0
		Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	2	—	1	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	222	148	66,7	34	15,3	40	18,0	0	0
		Ž	99	65	65,7	15	15,2	18	18,2	1	1,0
C65	Ledvični meh Renal pelvis	M	19	9	47,4	6	31,6	4	21,1	0	0,0
		Ž	14	5	—	4	—	4	—	1	—
C66	Sečevod Ureter	M	7	2	—	5	—	0	—	0	—
		Ž	9	7	—	2	—	0	—	0	—
C67	Sečni mehur Bladder	M	199	151	75,9	29	14,6	15	7,5	4	2,0
		Ž	70	48	68,6	12	17,1	7	10,0	3	4,3
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	1	—	1	—	0	—	0	—
		Ž	2	0	—	1	—	0	—	1	—
C69	Oko in očesni adneksi Eye and adnexa	M	8	7	—	1	—	0	—	0	—
		Ž	10	9	—	1	—	0	—	0	—
C70	Meninge Meninges	M	3	3	—	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—	0	—
C71	Možgani Brain	M	82	82	100	0	0	0	0	0	0
		Ž	73	73	100	0	0	0	0	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	—	0	—	0	—	0	—
		Ž	3	3	—	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	39	24	61,5	14	35,9	1	2,6	0	0
		Ž	108	86	79,6	19	17,6	1	0,9	2	1,9
C74	Nadledvična žleza Adrenal gland	M	3	1	—	1	—	1	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	0	—	2	—	2	—	1	—
		Ž	34	0	0	17	50,0	15	44,1	2	5,9
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	28	0	0	0	0	0	0	28	100
		Ž	17	0	0	0	0	2	11,8	15	88,2
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	51	0	0	0	0	51	100	0	0
		Ž	52	0	0	0	0	52	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	19	0	0	0	0	19	100	0	0
		Ž	19	0	0	0	0	19	100	0	0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	46	0	0	0	0	46	100	0	0
		Ž	47	0	0	0	0	47	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage (Ann–Arbor)							
I		II		III+IV		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C81	Hodgkinova bolezen Hodgkin's disease	M	36	5	13,9	18	50,0	11	30,6	2	6
		Ž	30	5	16,7	13	43,3	11	36,7	1	3,3
C82– C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	153	41	26,8	18	11,8	68	44,4	26	17,0
		Ž	131	23	17,6	20	15,3	58	44,3	30	22,9

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2010.

Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2010.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vsi NHL All NHL	M+Ž	284	0	3	0	0	5	1	7	7	8	13	17	31	26	25	47	40	54
		M	153	0	3	0	0	3	0	5	4	3	10	10	19	13	14	27	17	25
		Ž	131	0	0	0	0	2	1	2	3	5	3	7	12	13	11	20	23	29
141	Jezik Tongue	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
142	Slinavke Salivary glands	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
146	Orofarinks Oropharynx	M	4	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	3
147	Epifarinks Epipharynx	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
		Ž	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
151	Želodec Stomach	M	12	0	0	0	0	0	0	0	0	0	3	1	1	0	2	1	2	2
		Ž	15	0	0	0	0	0	0	0	0	1	0	1	1	1	3	2	1	5
152	Tanko črevo Small intestine	M	3	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
153	Debelo črevo Colon	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
154	Rektum Rectum	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
155	Jetra Liver	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
157	Trebušna slinavka Pancreas	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
170	Kosti Bone	M	3	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	1
		Ž	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
171	Mehka tkiva Soft tissues	M	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
173	Koža, drugi malignomi Skin, other malignancies	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1
		Ž	7	0	0	0	0	0	0	0	0	1	1	0	1	2	0	1	0	1
186	Modo Testis	M	5	0	0	0	0	0	0	0	0	0	0	1	0	2	1	1	0	0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
190	Oko Eye	M	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
191	Možgani Brain	M	7	0	0	0	0	1	0	0	0	0	0	2	2	0	2	0	0	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	1
193	Ščitnica Thyroid	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
194	Endokrine žleze, druge Endocrine glands, other	M	2	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
202	Bezgavke Lymph nodes	M	98	0	2	0	0	1	0	3	4	1	5	8	12	8	9	15	14	16
		Ž	86	0	0	0	0	1	0	2	3	3	2	5	9	8	7	13	17	16

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega in krvotvornega tkiva po verziji 2010 MKB-10, spolu in starosti, Slovenija 2010.

Table 10: Incidence of malignant neoplasms of lymphoid and haemopoetic tissue according to version 2010 of ICD-10, by sex and by age, Slovenia 2010.

Šifra MKB-10 ICD-10 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vse vrste All types	M+Ž	595	2	6	4	7	12	8	14	15	11	23	42	60	50	56	86	83	116
		M	321	1	5	2	3	8	3	12	7	6	15	25	38	29	32	48	38	49
		Ž	274	1	1	2	4	4	5	2	8	5	8	17	22	21	24	38	45	67
C81.0	Hodgkinova bolezen, nodularna oblika s prevladovanjem limfocitov Nodular lymphocyte predominant Hodgkin lymphoma	M	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81.1	Hodgkinova bolezen, nodularna skleroza Nodular sclerosis classical Hodgkin lymphoma	M	7	0	0	0	3	1	2	1	0	0	0	0	0	0	0	0	0	0
		Ž	17	0	1	2	1	2	4	0	3	0	2	1	0	1	0	0	0	0
C81.2	Hodgkinova bolezen, mešanocelična oblika Mixed cellularity classical Hodgkin lymphoma	M	25	0	0	2	1	1	1	3	1	2	1	2	3	3	3	0	1	1
		Ž	10	0	0	0	2	0	0	0	0	0	0	3	0	0	0	1	1	3
C81.4	Hodgkinova bolezen, oblika bogata z limfociti Lymphocyte-rich classical Hodgkin lymphoma	M	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
C81.9	Hodgkinova bolezen, neopredeljena Hodgkin lymphoma, unspecified	M	2	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C82.0	Folikularni limfom, stopnja I Follicular lymphoma grade I	M	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0	0
C82.1	Folikularni limfom, stopnja II Follicular lymphoma grade II	M	5	0	0	0	0	0	0	0	1	0	1	2	0	1	0	0	0	0
		Ž	6	0	0	0	0	0	0	0	1	0	1	1	1	1	1	0	0	0
C82.2	Folikularni limfom, stopnja III, neopredeljena Follicular lymphoma grade III, unspecified	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C82.6	Kožni limfom folikularnih celic Cutaneous follicle centre lymphoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C82.9	Folikularni limfom, neopredeljen Follicular lymphoma, unspecified	M	5	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0
C83.0	Drobnocelični limfom B Small cell B-cell lymphoma	M	16	0	0	0	0	0	0	0	0	0	0	2	2	2	1	3	3	3
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	3	1
C83.1	Limfom plaščnih celic Mantle cell lymphoma	M	12	0	0	0	0	0	0	0	0	1	1	0	1	4	0	3	2	0
		Ž	6	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	2	2
C83.3	Difuzni velikocelični limfom B Diffuse large B-cell lymphoma	M	70	0	0	0	3	0	2	1	1	5	4	8	5	8	12	9	12	
		Ž	52	0	0	0	1	1	0	0	0	1	4	4	4	3	8	9	17	
C83.5	Difuzni limfoblastni limfom Lymphoblastic (diffuse) lymphoma	M	2	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	
C83.7	Burkittov limfom Burkitt lymphoma	M	5	0	2	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C84.0	Fungoidna mikoza Mycosis fungoides	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1
C84.4	Periferni limfom T Peripheral T-cell lymphoma, not classified	M	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	
		Ž	9	0	0	0	0	0	0	0	0	1	1	1	0	1	0	1	4	0

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra MKB–10 ICD–10 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C84.6	Anaplastični velikocelični limfom, ALK pozitiven Anaplastic large cell lymphoma, ALK-positive	M	6	0	1	0	0	0	0	0	0	0	1	0	0	0	0	2	0	2
		Ž	8	0	0	0	0	0	0	0	1	0	1	0	0	4	0	0	1	1
C84.8	Kožni limfom T, neopredeljen Cutaneous T-cell lymphoma, unspecified	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C85.2	Mediastinalni (timični) velikocelični limfom B Mediastinal (thymic) large B-cell lymphoma	M	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0
C85.9	Ne-Hodgkinov limfom, neopredeljen Non-Hodgkin lymphoma, unspecified	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2
		Ž	10	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	3	5
C86.1	Hepatosplenični limfom T Hepatosplenic T-cell lymphoma	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C86.5	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C86.6	Primarne kožne CD30 pozitivne limfoproliferativne bolezni Primary cutaneous CD30-positive T-cell proliferations	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C88.0	Waldenströmova makroglobulinemija Waldenström macroglobulinaemia	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C88.4	Ekstranodalni limfom marginalne cone (MALTom) Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lyphoma]	M	16	0	0	0	0	0	1	1	1	1	1	3	1	1	3	1	2	
		Ž	14	0	0	0	0	0	0	0	1	0	1	0	1	2	6	1	2	
C90.0	Difuzni plazmocitom Multiple myeloma	M	55	0	0	0	0	0	0	0	0	0	1	6	6	5	6	12	7	12
		Ž	53	0	0	0	0	0	0	0	0	0	3	2	5	3	8	7	12	13
C90.2	Plazmocitom, ekstramedularni Extramedullary plasmacytoma	M	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90.3	Solitarni plazmocitom Solitary plasmacytoma	M	9	0	0	0	0	0	0	0	0	0	3	1	1	1	1	1	1	1
		Ž	7	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	1	1
C91.0	Akutna limfoblastna levkemija Acute lymphoblastic leukaemia [ALL]	M	6	1	1	0	1	1	0	0	0	0	0	0	1	0	0	0	0	1
		Ž	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
C91.1	Kronična limfocitna levkemija B Chronic lymphocytic leukaemia of B-cell type	M	49	0	0	0	0	0	0	0	0	0	2	2	7	5	8	6	12	7
		Ž	45	0	0	0	0	0	0	0	0	0	0	3	4	2	4	6	7	19
C91.4	Dlakastocelična levkemija Hairy-cell leukaemia	M	6	0	0	0	0	0	0	0	0	1	0	1	1	2	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C91.5	Limfom/levkemija T pri odraslih (HTLV-1 pozitiven) Adult T-cell lymphoma/ leukaemia (HTLV-1-associated)	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C91.6	Prolimfocitna levkemija T Prolymphocytic leukaemia of T-cell type	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C91.8	Burkittova levkemija zrelih B-celic Mature B-cell leukaemia Burkitt-type	M	2	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	12851	10497	81,7	8211	63,9	3774	29,4	3014	23,5
C00–C14	Usta in žrelo Mouth and pharynx	368	338	91,8	204	55,4	41	11,1	272	73,9
C15	Požiralnik Oesophagus	81	43	53,1	19	23,5	16	19,8	22	27,2
C16	Želodec Stomach	462	269	58,2	233	50,4	121	26,2	85	18,4
C18	Debelo črevo Colon	991	886	89,4	872	88,0	229	23,1	12	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	710	604	85,1	570	80,3	249	35,1	246	34,6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	156	34	21,8	17	10,9	18	11,5	3	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	156	55	35,3	50	32,1	12	–	1	–
C25	Trebušna slinavka Pancreas	321	107	33,3	53	16,5	76	23,7	8	–
C32	Grlo Larynx	120	113	94,2	53	44,2	2	–	100	83,3
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1241	902	72,7	217	17,5	497	40,0	573	46,2
C43	Maligni melanom kože Malignant melanoma of skin	469	464	98,9	463	98,7	2	–	24	5,1
C44	Druge maligne neoplazme kože Skin, other malignomas	2101	2054	97,8	1962	93,4	13	–	88	4,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	55	48	87,3	40	72,7	15	27,3	18	32,7
C50	Dojka Breast	1262	1225	97,1	1084	85,9	1110	88,0	681	54,0
C53	Maternični vrat Cervix uteri	142	133	93,7	104	73,2	11	–	70	49,3
C54	Maternično telo Corpus uteri	324	305	94,1	276	85,2	16	4,9	123	38,0
C56	Jajčnik Ovary	171	148	86,5	141	82,5	126	73,7	1	–
C61	Prostata Prostate	1262	1117	88,5	715	56,7	477	37,8	145	11,5
C62	Modo Testis	104	103	99,0	103	99,0	54	51,9	0	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	354	292	82,5	276	78,0	22	6,2	23	6,5
C67	Sečni mehur Bladder	269	240	89,2	237	88,1	39	14,5	26	9,7
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	163	142	87,1	135	82,8	65	39,9	88	54,0
C73	Ščitnica Thyroid gland	147	139	94,6	137	93,2	127	86,4	103	70,1
C81	Hodgkinova bolezen Hodgkin's disease	66	63	95,5	1	–	61	92,4	37	56,1
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	218	76,8	38	13,4	165	58,1	104	36,6
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	127	63	49,6	4	–	53	41,7	28	22,0
C91–C95	Levkemije Leukaemias	238	51	21,4	0	–	48	20,2	8	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by surgery during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12851	8211	573	229	294	2797	1041	1219	276	302	415	35	494	436	100
C00–C14	Usta in žrelo Mouth and pharynx	368	204	2	0	1	129	0	64	4	0	2	0	1	0	1
C15	Požiralnik Oesophagus	81	19	0	0	0	14	0	4	0	0	1	0	0	0	0
C16	Želodec Stomach	462	233	10	5	5	110	1	72	6	7	7	0	6	4	0
C18	Debelo črevo Colon	991	872	77	88	48	273	23	128	31	55	50	9	46	22	22
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	710	570	16	34	39	186	64	92	25	24	33	4	32	12	9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	156	17	0	0	0	12	0	5	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	156	50	3	1	1	25	1	15	0	1	2	0	1	0	0
C25	Trebušna slinavka Pancreas	321	53	0	0	0	33	1	19	0	0	0	0	0	0	0
C32	Grlo Larynx	120	53	0	0	0	31	0	22	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1241	217	0	0	0	154	0	44	0	0	0	0	0	12	7
C43	Maligni melanom kože Malignant melanoma of skin	469	463	45	17	33	141	39	47	11	7	29	4	14	61	15
C44	Druge maligne neoplazme kože Skin, other malignomas	2101	1962	209	72	49	685	28	161	120	62	171	3	79	315	8
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	55	40	3	2	0	5	18	4	1	1	3	1	1	1	0
C50	Dojka Breast	1262	1084	35	0	39	5	692	193	5	76	1	0	34	0	4
C53	Maternični vrat Cervix uteri	142	104	5	2	2	68	3	8	0	1	3	3	3	0	6
C54	Maternično telo Corpus uteri	324	276	30	5	8	117	23	46	3	5	11	6	11	0	11
C56	Jajčnik Ovary	171	141	14	3	6	56	25	19	3	3	4	2	1	0	5
C61	Prostata Prostate	1262	715	77	0	31	180	0	106	38	33	36	0	211	1	2
C62	Modo Testis	104	103	11	0	4	46	1	25	6	2	2	0	6	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	354	276	9	0	10	135	0	52	6	8	26	0	29	0	1
C67	Sečni mehur Bladder	269	237	16	0	10	119	0	28	13	12	26	0	13	0	0
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	163	135	0	0	0	116	0	18	0	0	0	0	0	0	1
C73	Ščitnica Thyroid gland	147	137	0	0	4	23	95	6	0	0	0	0	2	7	0
C81	Hodgkinova bolezen Hodgkin's disease	66	1	0	0	0	1	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	38	3	0	1	19	3	6	1	0	3	1	0	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	127	4	0	0	0	3	0	0	1	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	238	0	0	0	0	0	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that undergone multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2010, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po lokacijah raka in bolnici posega.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2010, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12851	3774	91	120	25	254	2600	408	40	79	48	42	48	19
C00–C14	Usta in žrelo Mouth and pharynx	368	41	0	0	0	1	40	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	81	16	0	0	0	0	15	0	0	0	0	0	0	1
C16	Želodec Stomach	462	121	0	0	0	4	117	0	0	0	0	0	0	0
C18	Debelo črevo Colon	991	229	5	0	0	2	207	5	2	0	0	7	0	1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	710	249	1	0	0	0	241	3	0	0	0	3	0	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	156	18	0	0	0	9	4	4	0	0	0	1	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	156	12	0	0	0	0	11	1	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	321	76	1	0	0	31	44	0	0	0	0	0	0	0
C32	Grlo Larynx	120	2	0	0	0	0	2	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1241	497	0	115	0	0	314	68	0	0	0	0	0	0
C43	Maligni melanom kože Malignant melanoma of skin	469	2	0	0	0	0	2	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2101	13	1	0	0	1	1	5	0	0	0	0	5	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	55	15	0	0	0	1	13	1	0	0	0	0	0	0
C50	Dojka Breast	1262	1110	11	0	11	0	813	208	1	54	0	10	0	2
C53	Maternični vrat Cervix uteri	142	11	0	0	0	0	11	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	324	16	0	0	0	0	13	3	0	0	0	0	0	0
C56	Jajčnik Ovary	171	126	0	0	0	0	105	21	0	0	0	0	0	0
C61	Prostata Prostate	1262	477	49	0	11	109	89	61	34	24	40	14	39	7
C62	Modo Testis	104	54	0	0	0	1	53	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	354	22	0	0	0	2	19	0	0	0	0	0	0	1
C67	Sečni mehur Bladder	269	39	4	0	0	12	19	1	0	0	0	3	0	0
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	163	65	0	0	0	2	63	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	147	127	0	0	1	8	114	0	0	0	0	0	4	0
C81	Hodgkinova bolezen Hodgkin's disease	66	61	0	0	0	7	53	0	0	0	0	0	0	1
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	165	2	0	0	6	148	6	0	0	1	1	0	1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	127	53	6	0	2	31	0	7	1	0	2	1	0	3
C91–C95	Levkemije Leukaemias	238	48	10	0	0	18	2	8	2	1	5	2	0	0

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that undergone multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2010.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2010.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	
C00	Vse lokacije	M+Ž	10369	27242	21095	26796	81316
C96	All sites	M	5410	13288	9011	8983	34584
		Ž	4959	13954	12084	17813	46732
C00–C14	Usta in žrelo Mouth and pharynx	M	246	503	325	412	1486
		Ž	63	180	150	178	571
C15	Požiralnik Oesophagus	M	35	42	21	18	116
		Ž	10	12	10	3	35
C16	Želodec Stomach	M	169	291	234	307	1001
		Ž	119	202	181	287	789
C18	Debelo črevo Colon	M	484	959	669	585	2697
		Ž	352	809	609	711	2481
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	384	866	561	508	2319
		Ž	212	611	390	554	1767
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	37	57	12	13	119
		Ž	25	20	4	9	58
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	26	44	18	21	109
		Ž	43	54	23	26	146
C25	Trebušna slinavka Pancreas	M	62	48	12	11	133
		Ž	70	46	20	10	146
C32	Grlo Larynx	M	99	258	212	283	852
		Ž	7	34	25	45	111
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	497	583	286	296	1662
		Ž	245	301	125	112	783
C43	Malignni melanom kože Malignant melanoma of skin	M	224	675	438	465	1802
		Ž	231	818	578	883	2510
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1017	3193	2418	2390	9018
		Ž	1044	3510	2823	3071	10448
C48–C49	Veživo in mehko tkivo Connective and soft tissue	M	15	71	66	150	302
		Ž	30	79	69	173	351
C50	Dojka Breast	M	10	19	20	28	77
		Ž	1208	3816	3563	4910	13497
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	131	429	692	2294	3546
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	308	896	1004	1860	4068
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	148	354	293	749	1544
C61	Prostata Prostate	M	1180	3563	1932	696	7371
		Ž	–	–	–	–	–
C62	Modo Testis	M	103	385	431	940	1859
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehcom Kidney with renal pelvis	M	192	509	349	372	1422
		Ž	84	263	220	325	892
C67	Sečni mehur Bladder	M	157	426	289	293	1165
		Ž	53	137	96	118	404
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M	59	88	63	151	361
		Ž	53	66	63	109	291
C73	Ščitnica Thyroid gland	M	37	95	107	137	376
		Ž	107	448	384	551	1490
C81	Hodgkinova bolezen Hodgkin's disease	M	34	90	106	272	502
		Ž	27	76	96	250	449
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	123	321	246	365	1055
		Ž	105	346	295	357	1103
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	50	113	46	20	229
		Ž	48	95	40	26	209
C91–C95	Levkemije Leukaemias	M	89	252	189	245	775
		Ž	74	194	163	255	686

* Pri posameznih lokacijah je pri prikazu prevalenca oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2008

- Baili P, Micheli A, De Angelis R, Weir HK, Primic Žakelj M, Pompe-Kirn V, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori* 94: 658–68.
- Bešič N, Černivc B, de Greve J, Lokar K, Krajc M, Novaković S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. *Genet Test* 2008; 12: 203–9.
- Chuang S, Hashibe M, Scelo G, Brewster DH, Pukkala E, Pompe-Kirn V, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 1543–9.
- Chuang S, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Pompe-Kirn V, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. *Int J Cancer* 2008; 123: 2390–6.
- Glumac N, Hočevnar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict nonsentinel involvement in cutaneous melanoma patients. *J Surg Oncol* 2008; 98: 46–8.
- Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Primic Žakelj M, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. *Eur J Cancer* 2008; 44: 1463–75.
- Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M, Primic-Žakelj M, et al. Improving cancer control in the European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2008. *Eur J Cancer* 2008; 44: 1457–62.
- Krajc M. Screening. In: Kovačič L, Zaletel-Kragelj L, eds. *Management in health care practice: a handbook for teachers, researchers and health professionals*. Laga: Hans Jacobs Publishing Company; 2008. p. 286–307.
- Krajc M, Teugels E, Žgajnar J, Goelen G, Bešič N, Novaković S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. *BMC Med Genet* 2008; 9: 83–91.
- Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. *Eur J Cancer* 2008; 44: 830–9.
- Primic-Žakelj M. Cancer epidemiology. In: Schrijvers D, Zakotnik B, eds. *ESMO handbook of cancer prevention*. London: Informa Healthcare; 2008. p. 1–9.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Bilban M, ed. *Zbornik prispevkov Cvahtetovih dnevov*. Ljubljana: Katedra za javno zdravje; 2008.
- Primic-Žakelj M, Zadnik V, Žagar T. Karcinom debelega črevesa in danke v Sloveniji in v Evropi (Colorectal cancer in Slovenia and in Europe). In: Luzar B, Cerar A, Štabuc B, eds. *Tumorji debelega črevesa in danke*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2008.
- Primic-Žakelj M, Žagar T. Cancer control in Slovenia: achievements, shortcomings and opportunities. In: Coleman MP, ed. *Responding to the challenge of cancer in Europe*. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008.
- Primic-Žakelj M, Žagar T, Zadnik V. Lung cancer in Slovenia (Pljučni rak v Sloveniji). *Endosk rev* 2008; 13: 5–13.
- Repše-Fokter A, Primic-Žakelj M. Auditing screening laboratories in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 20.
- Repše-Fokter A, Primic-Žakelj M. Cervical cancer screening in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 3.

- Robins G, Crabtree JE, Bailey A, Forman D, Pompe-Kirn V, et al. International variation in *Helicobacter pylori* infection and rates of oesophageal cancer. *Eur J Cancer*. 2008; 44: 726–32.
- Rojnik K, Naveršnik K, Mateovič-Rojnik T, Primic-Žakelj M. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. *Value Health* 11: 139–48.
- Sant M, Allemani C, De Angelis R, Carbone A, de Sanjose S, Pompe-Kirn V, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. *Eur J Cancer* 2008; 44: 579–87.
- Terčelj M, Aleš A, Rott T, Sever N, Prodnik L, Primic-Žakelj M, et al. DNA-based sputum cell image analysis for lung cancer in a clinical setting. *Acta Cytol* 2008; 52: 584–90.
- Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Primic-Žakelj M, Pompe-Kirn V, et al. Survival in patients with uveal melanoma in Europe. *Arch Ophthalmol* 2008; 126: 1413–8.
- Zadnik V, Ivanuš U, Florjančič M, Primic-Žakelj M. Vloga registra ZORA pri obvladovanju bremena raka materničnega vratu v Sloveniji (The role of ZORA registry in cervical cancer burden control in Slovenia). *Bilt-ekon organ inform zdrav* 2008; 24:179–83.
- Zadnik V, Primic-Žakelj M. Rak pri ženskah. In: Štabuc B, Primic-Žakelj M, Klemenčič M, Piškur J, eds. *Rak rodil*. Ljubljana: Zveza slovenskih društev za boj proti raku; 2008.
- Zadnik V, Žagar T, Drobne S, Primic-Žakelj M. Estimation of cancer burden in Brežice municipality, a community neighboring Krško nuclear power plant in Slovenia. *Croat Med J* 2008; 49: 257–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Ginekološki raki v Sloveniji (Gynecological cancers in Slovenia). In: Takač I, ed. *80 let hospitalne ginekologije in porodništva v Maribor: mednarodni znanstveni simpozij*. Maribor: Univerzitetni klinični center Maribor; 2008.
- Zver S, Zadnik V, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Int J Hematol*. 2008; 88: 227–36.
- Zwitter M, Primic-Žakelj M. Lung cancer in Europe. In: Parikh PM, ed. *Lung cancer*. Mumbai: Green Room Media & Event Management Services; 2008. p. 350–7.

2009

- Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation of cervical cancer screening in the member states of the European Union. *Eur J Cancer* 2009; 45: 2685–708.
- Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival information in Europe. *Eur J Cancer* 2009; 45: 901–8.
- Ciccolallo L, Licitra L, Cantu G, Gatta G, Pompe-Kirn V, Primic-Žakelj M, et al. Survival from salivary glands adenoid cystic carcinoma in European populations. *Oral Oncol* 2009; 45: 669–74.
- De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic-Žakelj M, et al. The EURO-CARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. *Eur J Cancer* 2009; 45: 909–30.
- Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic-Žakelj M, et al. The cure of cancer: a European perspective. *Eur J Cancer* 2009; 45: 1067–79.
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic-Žakelj M, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. *Eur J Cancer* 2009; 45: 992–1005.
- Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Primic-Žakelj M, et al. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann Oncol* 2009; 20: 564–73.
- Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic-Žakelj M, et al. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2009; available from: <http://www.ncbi.nlm.nih.gov/pubmed/19569047>.
- Nicula FA, Anttila A, Neamtiiu L, Primic-Žakelj M, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. *Eur J Cancer* 2009; 45: 2679–84.
- Pasanisi P, Hedelin G, Berrino J, Chang-Claude J, Primic-Žakelj M, Zadnik V, et al. Oral contraceptive use and BRCA penetrance: a case-only study. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 2107–13.
- Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže pomembne javnozdravstvene rezultate. *Onkologija* 2009; 13: 4–6.

- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčič V, Pižem J, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4. december 2009, Ljubljana. *Novosti v dermatopatologiji*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009.
- Primic-Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs). *Farm vestn* 2009; 60: 90–4.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed. *Rak prostate: zbornik predavanj*. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
- Primic-Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European Union. 2009; 18: 272.
- Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic-Žakelj M, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur J Cancer* 2009; 45: 1006–16.
- Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive cervical cancer in Slovenia. *Virchows Arch* 2009; 455 Suppl,1: S6–S7.
- Ronco G, van Ballegooyen M, Becker N, Chil A, Fender M, Primic-Žakelj M, et al. Process performance of cervical screening programmes in Europe. *Eur J Cancer* 2009; 45: 2659–70.
- Rosso S, De Angelis R, Cicolallo L, Carrani E, Soerjomataram I, Primic-Žakelj M, et al. Multiple tumours in survival estimates. *Eur J Cancer* 2009; 45: 1080–94.
- Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic-Žakelj M, et al. EURO-CARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. *Eur J Cancer* 2009 Apr; 45(6): 931–91.
- Snoj Z, Primic-Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer. *Depress Anxiety* 2009; 26: 544–9.
- Trapido EJ, Primic-Žakelj M, Pogačnik A, Uršič-Vrsčaj M, Krajc M, Lešničar H, et al. Critical factors influencing the establishment, maintenance and sustainability of population-based cancer control programs. *Tumori* 2009; 95: 637–45.
- Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic-Žakelj M, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. *Eur J Cancer* 2009; 45: 1042–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike Slovenije (Georeferenced data acquisition and usage in the cancer registry of Republic of Slovenia). *Bilt-ekon organ inform zdrav* 2009; 25 (izr. št.): 14.
- Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. *J Thorac Oncol* 2009; 4: 1148–55.
- Žagar T, Zadnik V, Primic-Žakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information from other state databases via electronic mediums). In: Orel M, ed. *Nova vizija tehnologij prihodnosti*. Ljubljana: Evropska hiša; 2009.

2010

- Bouvier A, Pompe-Kirn V. What reasons lie behind long-term survival differences for gastric cancer within Europe? *Eur J Cancer* 2010; 46: 1086–92.
- Chuang S, Pompe-Kirn V. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer* 2010; 102: 1190–5.
- EurocareWorking Group, Lepage C, Pompe-Kirn V, Primic-Žakelj M. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2010; 126: 2928–34.
- Kofol-Bric T, Zadnik V et al. Zdravje moških med 20. in 64. letom. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 80–6.
- Krajc M, Kadivec M, Hertl K, Primic-Žakelj M. V državnem presejalnem programu za raka dojk Dora do sedaj odkritih 86 rakov dojk. *Onkologija* 2010; 14: 104–10.

- Mihevc Ponikvar B, Zadnik V et al. Zdravje žensk med 20. in 64. letom. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 71–9.
- Primic-Žakelj M. Country-specific description: Slovenia. In: Obergrainer W, Vittadello F eds. Cancer mapping in Alpine regions: Austria, Italy, Slovenia, Switzerland: 2001–2005. Innsbruck: Department of Clinical Epidemiology of TILAK; 2010, 47–9.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA danes. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. Prvi izobraževalni dan programa ZORA z mednarodno udeležbo. Zbornik. Ljubljana: Onkološki inštitut; 2010, 9-15.
- Primic-Žakelj M, Zadnik V. Rak. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 96–100.
- Primic-Žakelj M, Zadnik V, Žagar T. Breme raka v Sloveniji. Naša lekarna 2010; 41: 22–8.
- Primic-Žakelj M, Zadnik V, Žagar T. Razširjenost raka v Sloveniji in Evropi. In: Rotar-Pavlič D. Obravnava bolnika z rakom v osnovnem zdravstvenem varstvu: zbornik predavanj, Bled, 24. april 2010. Ljubljana: Zavod za razvoj družinske medicine; 2010, 5–8.
- Rebolj M, Ivanuš U, Lynge E. Indicators of quality assurance in cancer screening - the case of cervical cancer = Kazalniki kakovosti presejalnih programov - primer presejalnega programa za raka na materničnem vratu. Bilt.-ekon. organ. inform. zdrav 2010; 26(2): 44-51.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Strojani Fležar M. Review of negative and lowgrade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. Cytopathology 2010; 22: 1–7.
- Rosso S, Gondos A, Zanetti R, Bray F, Primic-Žakelj M, Žagar T, Smalley G, Ponti A, Brewster DH, Voogd AC, Crocetti E, Brenner H; EUNICE Survival Working Group. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 2010; 46: 3351–7.
- Strojani Fležar M, Snoj V, Ivanuš U, Primic-Žakelj M. Standardizacija izvidov patologije materničnega vratu. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. Prvi izobraževalni dan programa ZORA z mednarodno udeležbo. Zbornik. Ljubljana: Onkološki inštitut; 2010; 21-23, 61–72.
- Šelb-Šemerl J, Mihevc Ponikvar B, Primic-Žakelj M, Rok Simon M, Tomšič S, Zadnik V. Zdravje starejših. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 87–91.

2011

- Anttila A, Bielska-Lasota M, Davidson T, Van Delden JJ, Von Karsa L, Primic-Žakelj M, et al. Determinants for a successful implementation of population-based cancer screening programmes. Brussels: European Science Advisory Network for Health, 2011.
- Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Pompe-Kirn V, et al. High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. Int J Cancer 2011; 129(1):173–9.
- Buzeti T, Djomba JK, Tomšič S, Gabrijelčič Blenkuš M, Ivanuša M, Zadnik V, et al. Neenakosti v zdravju v Sloveniji. Health inequalities in Slovenia. Ljubljana: Inštitut za varovanje zdravja, 2011.
- Gatta G, Van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Primic-Žakelj M, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47(17): 2493–511.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Pomen triaznega testa HPV. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 26–39.
- Kadivec M, Krajc M. Rezultati in kazalniki uspešnosti programa DORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 40–8.
- Krajc M. Prednosti in omejitve mamografskega presejanja. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 49–58.
- Krajc M. Epidemiologija raka dojk. In: Mamografska šola, 9. in 10. junij 2011. Ljubljana: Onkološki inštitut, SZD, Združenje radiologov Slovenije, 2011: 1–6.
- Krajc M. Kazalci kakovosti presejalnega programa za raka dojk. In: Farkaš-Lainščak J, ed. Z dokazi podprto javno zdravje: zbornik prispevkov. Ljubljana: Medicinska fakulteta, Katedra za javno zdravje, 2011: str 128.


- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. *Int J Cancer* 2011;129(8):1940–52.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 7–12.
- Primic-Žakelj M. Epidemiologija raka in stopnja preživetja v Sloveniji v populaciji do 39 let. In: Ribič-Pucelj M, ed. Ohranjanje plodne sposobnosti pri onkoloških bolnicah in bolnikih: zbornik. Ljubljana: Slovensko društvo za reproduktivno medicino, 2011: 1–4.
- Primic-Žakelj M, Ivanuš U. Presejanje za raka pri ženskah. In: Čeh A, ed. Presejalni testi pri ženskah in otrocih: zbornik predavanj z recenzijo. Ljubljana: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester – babic, 2011: 7–15.
- Primic-Žakelj M, Ivanuš U. Rezultati in kazalniki uspešnosti programa ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 13–7.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA v letih 2005-2010. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M, eds. 2. izobraževalni dan programa ZORA, Brdo pri Kranju, 8. april 2011. Zbornik. Ljubljana: Onkološki inštitut Ljubljana, 2011: 9–12.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka sečnega mehurja = Epidemiology of bladder cancer. In: Zupančič M, ed. Rak sečnega mehurja: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec, 2010: 7–12.
- Rotovnik Kozjek N, Kompan L, Soeters P, Oblak I, Mlakar Mastnak D, Zadnik V, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Clin Nutr* 2011; 30(5): 567–70.
- Uršič-Vrščaj M, Primic-Žakelj M, Ivanuš U. Novosti v programu ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 18–25.
- Velenik V, Štrbac D, Maučec Zakotnik J, Zadnik V. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Eur J Cancer* 2011; 47(Supp1): S267.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Geografska analiza incidence raka v Beli krajini in okolici: ugotavljanje morebitnega presežka incidence raka zaradi izpostavljenosti PCB-jem: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Pojavljanje raka v upravnih enotah Celje in Šentjur pri Celju: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Kovše K, Tomšič S, Primic-Žakelj M. Breme raka v občini Dolenjske Toplice: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Primic-Žakelj M. SLORA - spletna stran z epidemiološkimi podatki o raku. *Onkologija* 2011; 15(1): 61–3.
- Zadnik V, Primic-Žakelj M. Breme raka uroloških in reproduktivnih organov v Sloveniji. *Slov 2000 in rak* 2011; 8–12.
- Žagar T, Zadnik V, Primic-Žakelj M. Local standardized incidence ratio estimates and comparison with other mapping methods for small geographical areas using Slovenian breast cancer data. *Journal of Applied Statistics* 2011; 38(12): 2751–61.

2012

- Čuić M, Zadnik V. Prekomerna telesna teža in debelost kot dejavnik tveganja raka = Overweight and obesity as cancer risk factor. In: Babnik K, Kocbek M, eds. Slovenski dan dietetike: prva znanstvena konferenca z mednarodno udeležbo, Izola, 25. oktober 2012. Zbornik prispevkov. Koper: Založba Univerze na Primorskem, 2012: 63–8.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. *Radiol Oncol* 2012; 46(3): 258–64.

- Gregorič B, Zadnik V, Jezeršek Novaković B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. *Radiol Oncol* 2012; 46(2): 153–9.
- Ivanuš U, Primic-Žakelj M. Interlaboratory variability in HPV-positive rates in ASC-US/LSIL smears in the cervical cancer screening programme ZORA = Razlike med citološkimi laboratoriji v deležu HPV-pozitivnih izvidov APC-N/PIL-NS v presejalnem programu za raka materničnega vratu ZORA. In: Strojčan Fležar M, Luzar B, Gutnik H, Pižem J, Kocjan G, eds. *Novosti v citopatologiji: most med kliniko in diagnostično patologijo: Bridge between clinics and diagnostic pathology*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2012: 203–8.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. *Zbornik*. Ljubljana: Onkološki inštitut, 2012: 53–63.
- Ivanuš U, Primic-Žakelj M. Samoodvzem vaginalnega vzorca za test HPV pri neozdrivnih presejalnih programih raka materničnega vratu. *Onkologija* 2012; 16(2): 78–86.
- Ivanuš U, Primic-Žakelj M. Tretji izobraževalni dan programa ZORA. *Onkologija* 2012; 16(2): 98–100.
- Jarm K. Podrobna raziskava preživetja bolnikov z rakom danke v Sloveniji, zbolelih v letih 2003–2005: specialistična naloga s področja javnega zdravja. Ljubljana: Onkološki inštitut; 2012.
- Koivisto-Korander R, Scélo G, Ferro G, Mellemkjaer L, Hemminki K, Pompe-Kirn V, et al. Second primary malignancies among women with uterine sarcoma. *Gynecol Oncol* 2012; 126(1): 30–5.
- Kovač V, Zwitter M, Žagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. *Radiol Oncol* 2012; 46(2): 136–44.
- Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Primic-Žakelj M, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. *Breast Cancer Res Treat* 2012; 134(1): 363–70.
- Primic-Žakelj M, Ivanuš U. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. *Zbornik*. Ljubljana: Onkološki inštitut, 2012: 9–14.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: *Rak pri starostniku*. Ljubljana: Onkološki inštitut, 2012: 14–25.
- Primic-Žakelj M, Žagar T. Razširjenost, preprečevanje in zgodnje odkrivanje pljučnega raka. In: Matković M, ed. *Pacienti in pljučni rak - trendi in novosti*. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2012: 19–31.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. *Slov 2000 Rak* 2012: 6–9.
- Primic-Žakelj M. Razširjenost in pomen redkih rakavih bolezní. In: Primic-Žakelj M, ed. *Redki raki*. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–13.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Fležar MS. Review of negative and low-grade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathol Off J Br Soc Clin Cytol* 2012; 23(1): 23–9.
- Uršič-Vrščaj M, Ivanuš U. HPV testiranje. In: Smrkolj Š, ed. *Obnovitveni kolposkopski tečaj*, Ljubljana, marec 2012. *Zbornik*. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2012: 63–9.
- Zadnik V, Primic-Žakelj M. Epidemiologic data on cervical cancer. In: Takač I, ed. *Recent advances in cervical cancer*. Kerala: Transworld Research Network, 2012: 1–7.
- Zadnik V, Primic-Žakelj M, Krajc M. Breme raka v Sloveniji v primerjavi z drugimi evropskimi državami = Cancer burden in Slovenia in comparison with the burden in other European countries. *Zdr Vestn* 2012; 81(5): 407–12.
- Zadnik V, Žagar T, Primic-Žakelj M. Analiza vpliva točkovnih virov onesnaženja na zbolevanje za rakom v Zasavju = Analysis of the impact of point source pollution on cancer in Zasavje. In: Kraigher A, ed. *Zbornik predstavitev*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1.
- Žagar T, Primic-Žakelj M, Zadnik V. Slovenian maps of local standardized incidence ratio. In: 34th International Association of Cancer Registries Conference, 17–19 September 2012. Cork: The National Cancer Registry, 2012: 42.
- Žagar T, Zadnik V, Primic-Žakelj M. Možnosti raziskovanja vpliva bivalnega okolja na pojavljanje raka. In: Kraigher A, ed. *Zbornik predstavitev*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1–15.
- Žist A, Milanez T, Škrbinc B, Zadnik V, Šeruga B. Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja. *Onkologija* 2012; 16(2): 74–7.





POROČILO RR št. 52
REPORT No. 52
Ljubljana 2013
ISSN 1318-5845